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Abstract 
The HIV-1 envelope glycoprotein, Env, facilitates the translocation of the viral 
capsid across the cellular membrane.  Env is a trimer of hetero-dimers composed of a 
gp120 subunit and gp41 transmembrane protein.  The gp120 subunit binds the primary 
receptor, CD4, leading to conformational changes of Env that then promote binding to 
the coreceptor, principally CCR5 or CXCR4.  As the sole protein on the surface of the 
virion, Env is under continuous pressure from the host’s antibody response.  Two classes 
of antibodies target the highly conserved receptor-binding sites of gp120: CD4-binding 
site (CD4bs) and CD4-induced (CD4i) antibodies.  
Here we focus on inhibiting HIV-1 entry by targeting both the CD4- and 
coreceptor-binding sites.  In Chapter 2 we show that an improved CCR5-mimetic peptide, 
CCR5mim2-Ig, used in combination with CD4-Ig, neutralized HIV-1 isolates more 
potently than either inhibitor alone.  Similarly, greater neutralization was achieved by 
combining a CD4i antibody, E51, with a CD4bs antibody, VRC01.  We show that this 
increased potency derives from the ability of E51 to induce quaternary changes of the 
Env trimer, facilitating greater access of VRC01 to its epitope.  Our studies also 
underscore key mechanistic differences between CD4-Ig and CD4bs antibodies. 
Chapter 3 describes the usefulness of targeting both receptor-binding sites by 
characterizing a dual-acting inhibitor: eCD4-Ig.  eCD4-Ig consists of CD4-Ig fused at its iv 
 
C-terminus with CCR5mim1.  eCD4-Ig bound Env with higher avidity than CD4-Ig and 
its sulfopeptide-fusion inhibited the tendency of CD4-Ig to enhance infection.  The 
potency of eCD4-Ig is similar to or better than the best HIV-1 broadly neutralizing 
antibodies (bNAbs).  eCD4-Ig is also more broadly neutralizing than any current HIV-1 
bNAb, and it efficiently neutralized a panel of 38 HIV-1 isolates resistant to the best 
CD4bs bNAbs as well as SIV and HIV-2 isolates.  Lastly, eCD4-Ig retained its efficacy 
in vivo: it protected humanized mice from an HIV-1 challenge and was expressed by an 
adeno-associated virus (AAV) vector in rhesus macaques at levels greater than 100 
µg/mL.  Taken together, our studies highlight the advantages of targeting both receptor-
binding sites simultaneously and describe a new HIV-1 entry inhibitor with potential 
clinical use.    v 
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CHAPTER 1: INTRODUCTION 
 
The HIV-1 Pandemic and the Role of Entry Inhibitors 
 
   2 
 
1.A. The HIV-1 Pandemic 
Human Immunodeficiency Virus Type 1 (HIV-1) was identified as the cause of 
what is now known as Acquired Immunodeficiency Syndrome (AIDS) in 1981
1-3.  HIV-1 
is classified in the genus Lentivirus and in the family of Retroviridae.  Current data from 
the World Health Organization suggests there are approximately 35.3 million people 
worldwide living with AIDS
4.  In that same year, there were 2.3 million people newly 
infected with HIV-1 and 1.3 million AIDS related deaths
4.  In sub-Saharan Africa alone, 
prevalence rates exceed 10% in numerous countries totaling 22 million HIV-1 
infections
4,5. 
  HIV-1 infection is usually characterized with an initial acute primary infection 
where there is an infection of CD4+ T cells, dendritic cells, and macrophages and a spike 
in viral RNA load around 10
5 to 10
6 copies/mL of plasma around two weeks post 
infection
6.  The spike of viral RNA is followed by the reduction of free virus in the blood 
by CD8+ T cells and antibodies neutralizing virus.  The decrease in viral load reaches a 
set point of around 10
4 to 10
5 RNA copies/mL around four months post infection
7,8.  In 
untreated individuals, latent infection can last an average of 10 years as the virus 
continues to replicate in lymphoid organs.  However, the number of CD4+ T cells will 
decrease to levels below 200 cells/mL, indicating the disease has progressed to AIDS.  At 
these levels, the immune system cannot control opportunistic infections.  For example, 
the HIV-1 pandemic has led to the resurgence in tuberculosis infections.  The average 
survival rate for untreated individuals is about three years. 
Current anti-viral cocktail therapies are efficient at suppressing viral replication 
and increasing life expectancy of infected individuals.  However, of the 35 million people 3 
 
infected, less than 10 million of those individuals had access to anti-retroviral therapy.  
Individuals that are on the anti-retroviral therapy must take their medication daily with an 
average annual cost ranging from $11,000 to $23,000
9.  Until a conventional HIV-1 
vaccine is available, new therapies are continually examined in an effort to decrease 
treatment costs. 
1.B. HIV-1 Replication Cycle 
Viral entry   
HIV-1 entry is the first phase of the viral life cycle in which the viral capsid core 
translocates across the host cell membrane into the cytosol.  Entry is mediated by the 
viral envelope glycoprotein (Env), a trimer of non-covalently bound hetero-dimers of 
gp120 and gp41.  The precursor protein of Env, gp160, trimerizes and is cleaved by furin 
into gp120, the binding domain, and gp41, the transmembrane domain
10 (Figure 1.1A).   
  Entry initiates when the virus associates with the host cell.  This initial viral 
attachment to the host cell can be a low specificity binding event.  A number of 
attachment factors have been classified that help HIV-1 entry into host cells.  These 
attachment factors include the negatively charged heparan sulfate proteoglycans, which 
have been shown to bind Env nonspecifically
11.  Other attachment factors that have been 
identified are alpha-4-beta-7 integrins and dendritic cell-specific intercellular adhesion 
molecular 3-grabbing non-integrin (DC-SIGN)
12-14.  Unlike an actual receptor, these 
attachment factors are not required for the virus to gain entry and do not confer 
permissibility on non-permissive cell types.  Attachment factors are used for bringing the 
virus into closer proximity of the primary receptor necessary for entry
15. 4 
 
  HIV-1 uses CD4 as its primary receptor
16-18 (Figure 1.1B).  It was recently 
suggested that an Env cluster binds a patch of CD4 on the surface of the host cell
19.  CD4 
contacts the gp120 subunit of Env at a specific CD4-binding site
20,21.  Env then 
undergoes conformational changes that rearranges its variable domains including the 
V1/V2 loop and subsequently the V3 loop
22-24.  CD4 binding was initially thought to lead 
to the creation of the bridging sheet
25,26, but recent structural data suggests the bridging 
sheet is present in the unliganded gp120
27.  Once in the CD4-bound state, Env is primed 
to bind its coreceptor, principally the chemokine receptors CCR5 or CXCR4
28-31 (Figure 
1.1C).  Binding of the coreceptor triggers viral fusion with the host cell membrane.  CD4 
and coreceptor binding exposes gp41, and in particular its hydrophobic fusion peptide, 
which inserts into the target cell membrane and forms the pre-hairpin intermediate (PHI).  
Following insertion of the fusion peptide, the gp41 amino-terminal helical region (HR-N 
or HR1) that is inserted into the target cell can then fold at the hinge with the carboxy-
terminal helical region (HR-C or HR2) that is tethered to the virus.  The folding of the 
three HR1 and HR2 regions forms the six-helix bundle (Figure 1.1D) and brings the 
tareget cell membrane into close proximity of the viral membrane, promoting mixing of 
the lipids from each bilayer.  Lipid mixing of the two membranes ultimately leads to the 
formation of the fusion pore, providing access of the viral capsid to the cellular cytosol. 5 
 
 
Figure 1.1.  The HIV-1 entry process
32.  (A) Env is expressed on the viral membrane as a trimer of gp120 
and gp41 heterodimers.  (B) HIV-1 enters the cell by Env binding its primary receptor, CD4.  (C)  Env then 
undergoes conformational changes that promote binding to its coreceptor, principally CCR5 or CXCR4.  
(D) The fusion peptide of gp41 inserts into the target cell membrane and begins the formation of the six-
helix bundle.  This brings the host cell membrane in close proximity to the viral membrane for membrane 
fusion to occur.  (Adapted from Wilen CB, Tilton JC, and Doms RW, 2012
32).  
 
Reverse transcription 
  After entry into the cell, the virus initiates reverse transcription of its genome in 
the cytoplasm of newly infected cells.  Completion of reverse transcription requires the 
disassembly of the capsid core and formation of the reverse transcriptase complex 
(RTC)
33,34.  HIV-1 encodes and packages its own reverse transcriptase which uses the 
HIV-1 genomic RNA as its template and tRNA(Lys3) as its primer.  The HIV-1 primer 
binding site is about 180 nucleotides starting at the 5’ end of the genome.  During reverse 
transcription, RNase H actively degrades RNA that associates with transcribed DNA in 
an RNA-DNA complex
35,36.  The degradation of the RNA template exposes the newly 
synthesized minus-strand DNA.  Minus-strand DNA transfer occurs and acts as a second 
primer binding the purine-rich polypurine tract (ppt) at the 3’ end of the viral RNA 
genome
37.  The complementary DNA (cDNA) is synthesized while RNase H cleaves the 
majority of the viral RNA.  The ppt acts as the primer for plus-strand DNA synthesis 
which continues until the first 18 tRNA nucleotides are copied.  Once copied, RNase H 
degrades the tRNA and the plus-strand is moved to the R region of the 5’ end.  Extension 6 
 
of both the minus- and plus-strand DNA generates the double-stranded viral DNA 
necessary for integration
38. 
Nuclear import 
  After the RTC has transcribed the double-stranded viral DNA, the virus forms a 
stable pre-integration complex (PIC) consisting of the viral integrase protein (IN) as well 
as Vpr and Matrix (MA).  The PIC is trafficked to the nuclear periphery along 
microtubules
39.  Too large to be transported through nuclear pores, the actual mechanism 
by which the PIC enters the nucleus remains unclear.  HIV-1 infects non-dividing cells 
implying that the PIC is actively transported across the nuclear membrane.  In contrast, 
simpler retroviruses cannot infect non-dividing cells and rely on the breakdown of the 
nuclear membrane during mitosis to enter the nucleus
40. The PIC creates extensive 
changes to the nuclear membrane in order to be actively transported into the nucleus
41,42.  
There is evidence that HIV-1 utilizes the importin pathway by recruiting numerous host 
proteins to the nuclear membrane that facilitate nucleaer import.  These cellular factors 
include importin-α, importin-β, and importin 7
43-45. 
Integration 
  Once in the nucleus, the integration process is mediated by the virus IN protein, 
which enters the nucleus with the viral DNA as part of the PIC.  Integration occurs 
directly at the termini of the viral DNA which can be inserted into semi-nonrandom 
locations in the host cell chromosomal DNA.  Association with the host protein 
LEDGF
46,47 usually results in integration towards areas of active transcription
48.  IN 
catalyzes the 3’ processing of the viral DNA.  IN then joins the 3’ hydroxyl to the 5’ 
hydroxyl ends of the target DNA by a nucleophilic reaction on the target DNA 7 
 
phosphodiester backbone at the site of integration.  This is known as strand transfer
49.  
Finally, gap repair of the integrated DNA is completed by enzymes of the host cell DNA 
repair synthesis pathway.  These include a flap endonuclease which trims the 5’ end, a 
polymerase which fills the gap, and a ligase to close the nicked DNA.  Once the DNA is 
fully repaired, the chromatin is remodeled back into its nucleosomal form
50,51. 
Transcription of viral genes 
  Transcription from the integrated viral genome is regulated in both cell-type and 
differentiation-dependent manner through the binding of cellular and viral proteins to the 
5’ LTR, which serves as the promoter
52.  HIV-1 uses numerous host cell proteins, along 
with viral proteins, to form extensive transcriptional units.  HIV-1 uses complex 
alternative splicing to produce the wide range of transcripts needed to generate all the 
viral proteins.  The numerous transcripts are achieved through the use of four different 
splice donor and eight different splice acceptor sites.  Transcription begins with the 
processing of the early genes: tat, rev, and nef.  Tat binds transcription complexes at the 
5’ LTR for transcriptional regulation
53.  Rev binds a specific motif in the env gene termed 
the rev response element (RRE)
54-56.  Rev binding to the RRE
57,58 is essential for the viral 
replication cycle as it promotes the transport of the unspliced 9-kb and partially spliced 4-
kb viral mRNA out of the nucleus and into the cytoplasm.  The longer transcript serves as 
a genome for packaging and other transcripts are used for producing the structural viral 
proteins needed for assembly: Gag, Pol, and Env.  
Assembly and budding 
  In the last stage of the virus life cycle, the virus assembles all the elements 
necessary to produce an infectious virus.  Assembly occurs at the plasma membrane and 8 
 
is mediated by the Gag polyprotein
59.  Gag binds to the plasma membrane, concentrates 
Env to the membrane, and uses its RNA packaging sequence to ensure that two viral 
genomic RNA copies are packaged into the virion.  The Gag polyprotein assembles in 
spherical particles and as budding occurs, the viral protease (PR) acts on the polyprotein 
to produce Gag maturation
60.  The N-terminal domain of Gag is called MA, the domain 
that binds the plasma membrane and recruits Env
61.  The middle domain of Gag is the 
Capsid domain (CA), which forms the capsid shell of the mature viral core.  The 
nucleocapsid (NC) domain has two zinc finger motifs that hold the viral genome during 
assembly.  At the C-terminal end of Gag is the p6 region which recruits necessary parts 
of the cellular ESCRT pathway, like ALIX, as well as HIV-1 accessory proteins.  The 
viral protease cleaves the Gag precursor, inducing major changes in the virion to 
complete the maturation process.  Budding requires recruitment of components of the 
host cell ESCRT pathway to complete the release of viral particles from the host cell 
plasma membrane
62. 
Accessory proteins 
  For successful infection, HIV-1 utilizes accessory proteins to evade a host 
immune response.  The viral protein Nef can downregulate surface expression of CD4
63,64 
to avoid Env-CD4 interactions when the virus is budding, MHC-I to evade CD8+ effector 
T-cell function
65, and HLA-A and HLA-B to avoid natural killer (NK) cell function
66.  
Vif is used to target APOBEC3, a host restriction factor, for polyubiquitination and 
degradation
67.  HIV-1 uses Vpu to counteract immune responses, such as down regulation 
of Bst2/Tetherin
68 to keep viral particles from being tethered to the cell surface.  Like 
Vif, both Vpr and Vpu also target host cell factors for degradation by ubiquitination.  Vpr 9 
 
also functions in creating cell cycle arrest during the G2 phase.  In short, retroviruses 
have evolved numerous mechanisms to evade the host’s immune response. 
1.C. HIV-1 Envelope Glycoprotein 
Biosynthesis of HIV-1 Env 
HIV-1 Env is generated from the env gene encoded by the virus.  Env is 
synthesized as an approximately 845- to 870-amino acid precursor polypeptide
69.  An N-
terminal signal peptide traffics Env to the endoplasmic reticulum (ER) where it acquires 
numerous N-linked, high-mannose glycans
70,71.  Transport of Env out of the ER is 
delayed to facilitate proper folding and oligomerization through disulfide bonds
72,73.  Env 
oligomerizes into a trimeric complex
74, a common quaternary structure found in viruses 
that use type 1 fusion for entry.  Trimeric Env is then transported to the Golgi apparatus 
where it is furin-cleaved into its gp120 subunit and gp41 transmembrane domain
10,75,76, 
the components of mature Env.  The gp120 subunit contains most of the surface-exposed 
elements of Env including approximately 24 N-linked glycosylated residues
70.  The gp41 
domain consists of a membrane-proximal ectodomain region (MPER), a transmembrane 
domain responsible for anchoring Env to the viral membrane, and a long cytoplasmic tail 
at the C-terminus, which is necessary for Env incorporation into the virion.  There are 
about three to four N-linked glycans found on gp41
71,77.  Noncovalent interactions keep 
gp120 and gp41 together in the assembled trimer
78,79.  Env trimers are trafficked to the 
plasma membrane and incorporated into virions where about 7-14 of mature, intact Envs 
are actually expressed on an infectious particle
80,81.  Initially, Env is sparsely distributed 
over the virion and has little lateral movement because of the rigidity of the gag lattice. 
Following the maturation of gag, specifically when MA separates from CA, Env 10 
 
overcomes its movement restriction and clusters on the virion, a process mediated by its 
cytoplasmic domains
19.  Figure 1.2 represents the crystal structure of a soluble Env trimer 
highlighting the gp120 core, V1/V2 loops, V3 loop, gp41, and important glycosylation 
residues on gp120
82.  
 
 
 
Figure 1.2.  Crystal structure of a soluble trimeric Env
82.  Presented is the crystal structure of a soluble, 
cleaved trimeric Env.  The arrangements of the V1/V2 loops (orange) and V3 loop (red) as well as the 
location of gp41 (green) are highlighted.  The gp120 core of one gp120 monomer is in yellow.  The second 
and third gp120 monomers and gp41 proteins are shaded in grey.  Labeled are the key N-linked 
glycosylations on gp120 by which antibodies can bind to.  (Adapted from Julien JP et al., 2013
82). 
 
Receptor binding causes tertiary and quaternary conformational changes 
  As the sole protein on the viral membrane, Env is necessary to mediate fusion of 
target cell and virion membranes, enabling translocation of the capsid core into the 
cytosol.  To gain entry into a target cell, Env binds a series of receptors.  Following 
identification of HIV-1 as the etiological agent of AIDS, it was soon recognized that the 11 
 
primary target cell was CD4+ T-helper cells
16.  Later studies confirmed that the primary 
receptor for HIV-1 was CD4 itself
17,18.  CD4 is obligate but not sufficient for viral entry, 
due to the requirement of a coreceptor.  Nearly a decade passed until coreceptors for 
HIV-1 were identified.  Cocchi et al., showed that macrophage tropic HIV-1 isolates 
could be inhibited by the β-chemokines RANTES, MIP-1α, and MIP-1β
83.  At the same 
time, Feng et al. showed that a chemokine-like receptor, now known as CXCR4, was 
necessary for infection of laboratory adapted strains of HIV-1
31.  A number of groups 
subsequently showed that HIV-1 uses chemokine receptors as coreceptors that are 
necessary to drive viral fusion.  These chemokine receptors belong to the family of G 
protein-coupled receptors (GPCRs) and include CCR2b, CCR3, CCR5, CXCR4, GPR1, 
GPR15 (Bob), and STRL33 (Bonzo)
28-30,84-86.  Principally, HIV-1 isolates use CCR5 as 
its coreceptor, while lab-derived isolates and isolates found late in infection acquire the 
ability to use CXCR4.  Isolates that use CCR5 as their coreceptor are termed R5 viruses 
while isolates that use CXCR4 as their coreceptor are termed X4 viruses and those 
isolates that can use both are R5X4 viruses
87.  A key commonality of HIV-1 coreceptors, 
relevant to the work described herein, is that they are tyrosine sulfated at their N-
termini
88,89, a property which facilitates efficient HIV-1 entry.   
As stated, Env consists of a gp120 subunit and gp41 transmembrane domain.  The 
gp120 subunit is involved in receptor- and coreceptor-binding and is heavily 
glycosylated.  There are five highly variable regions termed V1-5 as well as five more 
conserved regions
90.  V1-4 are bounded by disulfide bonds and described as loops.  The 
architecture of gp120 consists of an inner domain formed by the conserved regions, the 
glycosylated outer domain, and bridging sheet that comprises four anti-parallel β-strands.  12 
 
The gp120 core interacts with the gp41 stalk while a portion of the gp41 stalk is exposed 
on the viral membrane called the membrane-proximal external region (MPER). 
  The states of Env under different conditions has been extensively studied.  In 
particular CD4-bound and CD4-free states of gp120 and of Env have been described and 
characterized.  The binding site of CD4 is within a recessed pocket of gp120 that is 
somewhat protected by the variable loops
91.  One of the critical contacts between CD4 
and gp120 is in a deep cavity of gp120, containing a highly conserved GGD(P/L)E motif, 
which is filled by CD4 phenylalanine 43
25,91.  Conserved contact residues critical for CD4 
binding surround this pocket.  Unbound, trimeric Env assumes a “closed” conformation 
with the V1/V2 loop stumps positioned near the center of the trimer (Figure 1.3A-B)
22-24.  
Binding of CD4 to gp120 rotates gp120 out from the central access of the trimer and the 
V1/V2 and V3 loops are repositioned creating an “open” conformation (Figure 1.3C-D)
22-
24.  Repositioning of the V3 loop affords greater access to the coreceptor binding site, as 
is visible in the structure of the coreceptor-binding antibody 412d complexed with 
gp120
92.  Early evidence suggested that the bridging sheet did not form until post-CD4 
binding
25,26.  However, newer data suggests that the bridging sheet may exist even in the 
absence of CD4 binding and that it may be considered its own unique domain of gp120
27.   13 
 
 
Figure 1.3.  The closed and open states of Env
22.  Shown are the cryo-EM diagrams of Env in various 
states.  (A and B) When unbound, Env assumes a closed conformation.  (C and D) Upon CD4 binding, 
Env is changed into an open conformation with a distinct repositioning of the V1/V2 loops (red dots) and 
V3 loops (asterisk).  (E and F) Binding of 17b, whose epitope is the coreceptor-binding site, induces the 
same open conformation produced by CD4 binding with the same repositioning of the V1/V2 loops and V3 
loop.  (Adapted from Tran EE et al., 2012
22). 
 
  Although binding of CD4 induces an open conformation advantageous for 
coreceptor binding, antibodies binding the coreceptor-binding site also put the trimer in 
the same open conformation (Figure 1.3E-F)
22.  However, the coreceptor binding site is 
protected by the V1/V2 loops, limiting access to this site
93.  The co-crystal structure of 
the 412d in complex with gp120 localized two sulfated tyrosines of 412d to a highly-
conserved sulfotyrosine-binding pocket of gp120
92.  It is presumed that the sulfotyrosines 
of CCR5 and other coreceptors target this pocket in a similar manner. 14 
 
1.D.  Sequence Diversity of Env 
HIV-1 isolates are categorized into clades based on env gene sequence 
  The pandemic HIV-1 strains are all classified as part of the “main group” (Group 
M), which derive from an ancestral strain closely related to SIV chimpanzee
94.  Non-
pandemic HIV-1 strains have been assigned into group O (for “outlier”) and group N (for 
“non-M, non-O”).  Group M strains can be further subtyped into clades A through K 
based on the env gene sequence.  Isolates that have recombined are designated as 
circulating recombinant forms (CRF) with the clades used to form the isolate.  Certain 
clades are predominate in different regions of the world.  For example, Subsaharan Africa 
and India have a majority of clade C isolates while clade B is found in Europe and the 
Western Hemisphere. 
HIV-1 isolates are categorized into tiers based on neutralization resistance 
  The clade format organizes HIV-1 isolates based on sequence.  However, 
neutralization resistance varies from isolate to isolate within a clade.  Recently, HIV-1 
isolates have been categorized into a 3-tier system based on neutralization sensitivity 
against plasma pooled from HIV-1(+) individuals
95.  Tier 1 isolates are the most 
neutralization sensitive and tend to be lab-adapted strains.  Most HIV-1 isolates are 
defined as tier 2, while a small group – those most neutralization resistant to pooled sera 
– falls into the tier 3 category. 
1.E.  Mechanisms of Neutralization Resistance 
Sequence diversity 
The properties of Env complicate efforts to develop an effective HIV-1 vaccine. 
The virus has a high mutation rate because of its low-fidelity RT.  RT introduces 15 
 
approximately one new mutation per copied viral genome
96.  Diversity can also be 
generated through insertions, deletions, and recombinations between the copackaged 
genomes, all of which can be observed in Env.  The constant mutation of Env, along with 
its structural features that promote immune evasion, has created a challenge for 
developing a vaccine that will induce broadly neutralizing antibodies (bNAbs) against 
HIV-1.  The variable loops in particular exhibit very high sequence diversity, including 
variation in their length
97.  Because the variable loops are the most exposed parts of Env, 
mutations in these domains can quickly lead to antibody escape
98, without loss of fitness 
to the virus. 
The glycan shield 
  In addition to sequence diversity of the variable loops, the numerous 
glycosylations on Env present another obstacle.  There are approximately 24 N-linked 
glycoslyation sites on gp120 and 3-4 glycosylation sites on gp41
70,71.  The density of 
glycans on the surface of Env creates a “glycan shield” that limits access of antibodies to 
Env
99.  HIV-1 antibodies target glycans on gp120, however, the virus can readily escape 
these antibodies through continual mutation of glycosylated residues
100-102.   
Conserved areas of Env are difficult to access 
  The complex structure of Env creates problems for accessing the conserved areas 
even without the presence of glycans.  The receptor- and coreceptor-binding sites are two 
of the most conserved sites on Env.  Not only is the CD4-binding site difficult to access 
because of the V1/V2 loops
21,103 and nature of the closed trimeric structure, but it is also 
in a recessed cavity of gp120
20.  Another challenge is the sequence diversity around the 
cavity.  These residues, not important for CD4-binding, are part of the epitopes of most 16 
 
CD4-binding site antibodies, and can easily mutate, leading to viral escape.  The 
coreceptor-binding site is also blocked by the variable loops and has a much smaller 
conserved pocket at the base of the V3 loop.  A final relatively conserved epitope is the 
MPER region.  In contrast to influenza hemaglutinin (HA), whose gp41 analogue HA2 
has a long accessible stalk, gp41 has a short and relatively inaccessible gp41 epitope.   
Antibodies that bind a highly conserved region on gp41 tend to be broad, but they also 
bind the viral membrane
104-106.  The epitopes of these MPER antibodies tend to be most 
accessible during the process of fusion, and it is thought that smaller peptides might be 
more efficient than antibodies
69.   
Entropy cost for binding the receptor-binding sites 
  As mentioned, binding of both CD4 and coreceptor antibodies induces 
conformational changes to Env, and there is a free energy barrier to these changes.  
Antibodies targeting either receptor-binding site region might stabilize Env in the CD4-
bound state, imposing an entropy cost similar to that seen with CD4 (~50 kcal/mol)
91. 
This entropy cost diminishes antibody affinity, and has been termed “conformational 
masking” whereby Env uses energetics to “hide” critical conserved epitopes. 
1.F.  HIV-1 Entry Inhibitors 
Env is the sole viral protein expressed on the viral membrane, and thus the only 
one that can be targeted by proteins to prevent entry into host cells.  As mentioned, Env 
uses a number of strategies that allow the virus to escape inefficient pressure from a 
single inhibitor.  With numerous domains, multiple distinct glycosylation sites, and two 
receptor-binding sites, there are many epitopes on Env to inhibit viral entry.  Described 17 
 
below are different categories of HIV-1 entry inhibitors that target various epitopes on 
Env. 
Clinical entry inhibitors 
There is currently an FDA approved peptide that is part of a combinational drug 
therapy, T20 (Fuzeon/Enfuvirtide), a 36-amino acid peptide that modeled after HR2 of 
gp41
107.  Because of its similarity to HR2, T20 competes with HR2 in binding HR1 and 
block viral fusion to the host cell membrane.  The heptad repeats of gp41 are hidden 
within the trimeric complex and thus, T20 can only access HR1 during the fusion 
process.  It is worth noting that the T20 epitope can be induced by other inhibitors, like 
sCD4 and CCR5mim1-Ig
108,109. 
Another way to block entry is to target the receptors.  Maraviroc (UK 427,857) is 
another FDA approved drug that is a CCR5 antagonist
110.  Individuals infected with R5 
virus treated with maraviroc over 10 days saw a decline in viral titers at levels greater 
than 1.6 log10 in plasma HIV-1 RNA
111.  The efficacy of maraviroc was examined in two 
phase 3 trials that resulted in a drop in plasma HIV-1 RNA around 0.8 log10 copies/mL in 
those individuals receiving treatment
112,113.  However, there was a tendency individuals 
treated with maraviroc to see coreceptor switching as X4 viruses started to emerge
113.  
Other CCR5 antagonists currently being evaluated for FDA approval include vicriviroc
114 
and cenicriviroc
115.  There are currently two small molecules that are being evaluated as 
potential CXCR4 drugs, AMD3100 and AMD11070.  However, the problem with 
CXCR4 inhibitor treatment is that X4 viruses are normally present with R5 viruses
116,117.  
Treating with combinations of CCR5 and CXCR4 inhibitors might be more effective. 18 
 
Antibodies targeting CD4 and coreceptors have also proven effective.  A 
humanized anti-CD4 antibody, ibalizumab (iMab), binds to domain 2 of CD4 and 
decreases the flexibility of CD4
118.  iMab was able to reduce viral load in treated 
inviduals up to 1.5 log10 RNA copies/mL
119.  However, resistance emerged about 9 weeks 
post treatment
120.  Like iMab, PRO 140 is a humanized antibody but it binds CCR5, 
blocking gp120 attachment to the coreceptor
121,122.  Individuals treated with PRO 140 
saw an average reduction of 1.8 log10 HIV-1 RNA copies and no toxicity was 
observed
123.  Both PRO 140 and iMab have undergone phase 2 clinical studies. 
Soluble CD4 
Identification of CD4 as the HIV-1 primary receptor led to initial studies showing 
that a soluble form of CD4 (sCD4) could bind gp120 and prevent syncitia formation
124.  
Numerous in vitro studies showed that sCD4 could also prevent viral entry
125-128.  
Importantly, it was shown that, unlike cell-expressed CD4, sCD4 did not have high 
affinity for MHC class II, and therefore it did not interfere with MHC class II association 
with the T cell receptor
124.  More recently, N4, a rhesus form of two-domain sCD4 fused 
to an immunoglobulin G2 (IgG2) Fc region, showed its effectiveness in vivo as it 
protected 2 of 3 rhesus macaques from an SIVmac316 challenge
129.  However, sCD4 
enhanced SIV infection when used as a treatment
130.  In human patients, it was shown 
that antibodies are generated against sCD4
131, which can hinder its ability to bind and 
neutralize virus.  sCD4 has an advantage over other inhibitors in that it binds only the 
conserved sites on gp120. However, sCD4 binds most HIV-1 isolates with lower affinity 
than neutralizing antibodies, and high concentrations of sCD4 are necessary to 
completely neutralize primary HIV-1 isolates
132.  Large doses of sCD4-IgG2 were 19 
 
necessary to reduce viral loads in HIV-1(+) children and adults, and in some cases 
suppression to below detectable levels was observed.  Although efficacy of sCD4-Ig 
treatments was limited, no adverse effects of sCD4-Ig treatment were observed in these 
trials. 
HIV-1 broadly neutralizing antibodies 
After HIV-1 is transmitted to a new host, there is a rapid peak in viral load.  At 
this stage (the acute stage), CD4+ T cell levels decline but a CD8+ T-cell response drops 
viral loads down to a set point.  As early as 12 days post infection, the host starts to 
mount an antibody response against the virus.  However, these are only HIV-1 specific 
binding antibodies that do not have neutralizing capability.  These binding antibodies 
usually develop around four to six weeks post infection.  The first anti-Env antibodies 
detected are IgM anti-gp41 antibodies.  Next, non-neutralizing antibodies targeting the 
V3 loop are generated and followed by weak neutralizing anti-V3 antibodies.  Viremia is 
normally held in check during the asymptomatic portion of the infection and allows for 
neutralizing antibodies (NAbs) to develop.  Most NAbs target the variable regions of Env 
with others targeting the CD4-binding site and MPER regions.  HIV-1 broadly 
neutralizing antibodies (bNAbs) can take from months to years to develop.  Continual 
generation and development of HIV-1 antibodies allows the virus to escape the host 
immune response, leading to CD4+ T cell depletion to the point of AIDS. 
Many antibodies are generated against Env, but very few are efficient NAbs and 
many of those that lack breadth.  HIV-1 broadly neutralizing antibodies (bNAbs) are 
believed to take from months to years to develop.  HIV-1 bNAbs have been under intense 
focus in recent years as new technologies and techniques have helped identify a few 20 
 
classes as bNAbs.  Most groups looking to screen for bNAbs have used patient sera that 
shows high neutralization reactivity against HIV-1 isolates.  In the early 1990s, phage 
display technology was used for combining heavy chains and light chains from one elite 
controller and it was through this method that the first bNAb was identified
133,134.  More 
recent techniques have used gp140 trimers for selecting antibodies based on binding
135.  
The problem with this technique is that most antibodies identified by trimer binding are 
efficient neutralizers of tier 1 isolates but lack potency against many tier 2 and most tier 3 
isolates.   
A newer screen technique was used by Walker et al. to identify what was the first 
of many broader and more potent bNAbs
100.  This screen obtained and stimulated a large 
amount of B cells from an infected patient, and the resulting antibodies produced by the 
B cells were tested for neutralization against 2-4 HIV-1 isolates.  The best neutralizers 
were then cloned out and further characterized against a larger panel of HIV-1 isolates.  
Another novel technique was described by Wu et al. who started with a YU2 gp120 core 
(lacking variable loops 1 to 3) and resurfaced the outer domain of Env with SIV residues 
except for the CD4-binding site
136.  With this resurfaced stabilized core (RBC3), 
antibodies directed against the CD4bs were identified, with some as bNAbs.  This was 
followed by Scheid et al. who developed a 2CC core where a YU2 gp140 trimer lacking 
variable loops 1 to 3 was used for binding memory B cells from patients with highly 
efficient sera
137.  New primer sets made to have a larger coverage were then used to clone 
out the heavy and light chains of the antibodies from the B cells selected in this screen.  
The 2CC core differed from the RBC3 core in that, excepting the variable loop deletions, 21 
 
gp140 was unaltered.  This allowed Sheid et al. to identify antibodies targeting sites other 
than the CD4bs. 
These newly identified HIV-1 bNAbs have encouraged efforts to develop an HIV-
1 vaccine.  Identifying these bNAbs demonstrated that there a few sites of vulnerability 
of Env.  These sites include the CD4-binding site (CD4bs), glycosylation of N332 on the 
V3 loop, glycosylation of N160 on the V1/V2 loop, and the MPER region (Figure 1.4).  
Characterizing HIV-1 bNAbs has also revealed key features of these antibodies, for 
example long CDR-H3s (heavy chain complementarity determining region 3) and high 
amounts of somatic hypermutation.  The different classes of HIV-1 antibodies are 
discussed below.   
 
Figure 1.4.  The epitopes on HIV-1 Env
138.  In grey is the cryo-EM tomogram of HIV-1 Env isolate Bal 
103 fitted with gp120 monomers in the CD4-bound state 
139 and modeled with glycosylated residues.  The 
numerous epitopes on Env are diagramed: red – the CD4-binding site; blue – N322 on V3; green – N160 on 
V1/V2; cyan – the MPER region; and orange – the sulfotryrosine-binding pocket.  (Adapted from Kwong 
PD and Mascola JR, 2012
138). 
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CD4-binding site antibodies  
Of the epitopes mapped on HIV-1 Env, the CD4-binding site (CD4bs) is an 
especially important target because it is conserved and antibodies directed against this 
region directly block CD4 binding.  The bNAb b12 was first identified in 1994 from a 31 
year-old male who had been HIV seropositive but showed no signs of symptoms for six 
years
134.  Of note, b12 bound the CD4-binding site but structural data showed that it did 
not induce the CD4-bound state
26.  Although it doesn’t induce the CD4-bound state, b12 
does produce conformational changes of gp120 which causes it to have a high 
perturbation factor for binding Env
140.  Binding of less potent CD4bs antibodies, F015 
and b13, also produce substantial conformational changes on Env but are different than 
the changes produced by b12
141.  Interestingly, the heavy chain of b12 contains a large 
CDR-H3 that binds gp120 in close proximity to the coreceptor-binding site.  As a 
possible artifact of phage display, b12 does not use its light chain for any contacts on 
gp120
26.  b12 is extremely efficient against clade B isolates, neutralizing ~75% of 
isolates tested.  However, the breadth of b12 is limited to neutralizing ~35% of all 
isolates assayed
136. 
A more potent CD4bs antibody, VRC01, was isolated in 2010.  Wu et al. used a 
“bait” YU2 scaffold gp120 where the CD4 binding site was conformationally stable and 
resurfaced without glycosylation.  Among the antibodies identified, VRC01 neutralized 
~90% of the isolates it was tested against with a mean IC50 of 0.3 ug/uL
136.  In common 
with b12, VRC01 shows a high affinity for both the bound and unbound conformations of 
gp120
142.  Structural analysis indicates that VRC01 covers ~98% of the CD4 binding 
site
142, as seen in Figure 1.5. 23 
 
         Since the discovery of VRC01, more neutralizing antibodies have been isolated 
from HIV-1 infected patients.  A more potent CD4bs antibody, PGV-04, has been 
characterized and shown to share the same VH1-2 germline origin as VRC01
143.  Using 
the 2CC core, Scheid et al. identified NIH45-46 and 3BNC117, both of which have 
shown to be more potent than VRC01
137.  NIH45-46 may be more potent than VRC01 
because of its ability to bind the bridging sheet of gp120
144.  An engineered NIH45-46 
variant containing a G54W mutation in its CDR-H2, bound gp120 with higher affinity, 
presumably by occupying the Phe43 pocket of gp120
144.  The G54W mutation also 
increased the potency of the NIH45-46, gaining the ability to neutralize previously 
resistant viruses.  Further mutations of the NIH45-46 light chain have improved NIH45-
46
G54W and were shown to neutralize NIH45-46 escape isolates
145.  Numerous other 
antibodies were characterized through these studies including 12A12, HJ16, VRC03, and 
8ANC195.  The proliferation of CD4bs antibodies identified offers the promise that 
CD4bs antibodies can be generated even with all the strategies Env employs to hide the 
CD4-binding site. 24 
 
 
Figure 1.5. Footprints of CD4-binding site antibodies.  The footprints of CD4, b12, VRC01, NIH45-46, 
and 3BNC117 are modeled onto a gp120 monomer in the CD4-bound state.  The CD4 footprint is in red, 
antibody footprint is in blue, and overlapping contact residues are purple.  Also labeled on the CD4 
footpring model are the sulfotyrosine-binding pocket (green) and V3 loop.  Coordinates for the models are 
as follows: CD4 – 2QAD; b12 – 2NY7; VRC01 – 4LST; NIH45-46 – 3U7Y; 3BNC117 – 4JPV.  Modeling 
was done using Chimera. 
 
Glycan-dependent antibodies  
The isolation and characterization of the monoclonal antibody 2G12 identified a 
novel glycosylation epitope on Env
146.  2G12, originally described as a broadly 
neutralizing antibody, was found to bind to N-linked carbohydrates on the C2, C3, C4, 
and V4 regions of gp120.  In 2009, Walker et al. described two novel bNAbs, PG9 and 
PG16, that neutralized 79% and 74% of isolates tested, respectively
100.  Structure data 
indicated that PG9 binds two N-glycans, N156 and N160, as well as a strand on the 25 
 
V1/V2 loop of gp120 and the large CDR-H3 of PG16 forms a “hammer head” shape that 
is important for its potency
139,147.  Interestingly, PG9 and PG16 have a unique 
neutralization profile where they do not completely neutralize certain HIV-1 isolates, 
presumably through incomplete glycosylation of Env
148.  Another feature of PG9 and 
PG16 is that they bind trimeric Env efficiently but not monomeric gp120
100.  Since the 
discovery of PG9 and PG16, other bNAbs targeting the V1/V2 loop have been identified, 
including CH01-04 and PGT141-145
102,149. 
Walker et al. followed up their PG9 and PG16 with a PGT series of antibodies. 
The most potent from this group, including PGT121, PGT122, and PGT128, targeted the 
N332 glycan at the base of the V3 loop
82,102,150.  Separately, Mouquet et al., described a 
different series of N332 antibodies based on the antibody 10-1074
151.  The difference 
between the PGT121-series and 10-1074 is that the 10-1074 series is completely 
dependent on a glycosylated N332 residue whereas the PGT121-series uses a more 
complex epitope.  The crystal structure of a soluble, cleaved HIV-1 Env in complex with 
PGT122 determined this epitope to be at the base of the V1 and V3 loops as well as the 
glycosylated residues N137, N156/173, N301, and N332
82.  Although there are 
differences between PG9/PG16, PGT-series, and 10-1074-series of antibodies, it is 
important to note that these glycan-dependent antibodies show that the glycan shield 
itself can be efficiently targeted for neutralization. 
MPER antibodies 
  The conserved MPER region of gp41 serves as another vulnerable site for 
antibodies.  Notable MPER antibodies include 2F5
104, 4E10
105, and 10E8
152.  Of these, 
10E8 showed great breadth, neutralizing 98% of the isolates tested.  10E8 was initially 26 
 
described to be different than historical MPER antibodies in that it did not bind lipid and 
was not autoreactive.  However, it was recently reported that 10E8 does bind lipid 
bilayers through its CDR-H3
106.  Like 4E10 and 2F5, 10E8 binds a fusion-intermediate of 
gp41 indicating a common mechanism by which MPER antibodies bind gp41.  MPER 
antibodies are of considerable scientific and therapeutic interest because among bNAbs, 
they uniquely target a gp41 epitope, and they block gp41 conformational changes 
necessary for fusion. 
The gp120-gp41 epitope 
  A relatively new antibody epitope was defined to include both gp120 and gp41.  
bNAbs targeting this site include 8ANC195
137, PGT151
153, and PGT152
153.  The gp120-
gp41 epitope was first described through the characterization of m43, an antibody derived 
from phage display that neutralized 34% of the isolates assayed
154.  However, it was 
unclear whether m43 contacted both the gp120 and gp41 subunits simultaneously.  The 
crystal structures of 8ANC195 and PGT151 definitively showed that these antibodies 
interact with both subunits on the Env trimer
155,156.  The breadth of these antibodies is 
slightly less than the CD4bs, glycan-dependent, and MPER antibodies as 8ANC195, 
PGT151, and PGT152 neutralized 66%, 66%, and 64% of a panel of HIV-1 isolates, 
respectively
137,153.  Similar to PG9 and PG16, PGT151 and PGT152 both have 
incomplete neutralization behavior
153.  Yet, the gp120-gp41 epitope could be another 
target for vaccine design. 
CD4-induced antibodies 
Before the discovery of the HIV-1 coreceptors, a group of HIV-1 antibodies was 
identified, whose binding to gp120 is increased by the binding of CD4
157.  The epitope of 27 
 
these antibodies was later identified as the coreceptor-binding region of gp120.  Because 
the binding of CD4 to gp120 induces the binding of these antibodies, this class of 
antibodies was called CD4-induced antibodies (CD4i).  These antibodies bind the 
coreceptor region of gp120 and some do so using sulfated tyrosines
158, presumably 
mimicking the coreceptor.  CD4i antibodies commonly have long CDR-H3s and most 
originate from the germline precursor variable gene VH1-69
159.  The best characterized 
CD4i antibodies are 17b and 48d, two antibodies with weak neutralizing capabilities 
which neutralize X4 lab-adapted strains rather than most primary R5 strains
157.  The 
CD4i antibody E51 was shown to block CCR5 binding site and epitope mapping located 
the E51-binding site to the bridging sheet and the base of the V3 loop
160.  Like E51 and 
the CCR5 coreceptor, the CD4i antibody 412d also uses sulfated tyrosines to achieve 
binding to gp120
161, and binds an epitope similar to that of E51.  Both E51 and 412d are 
more potent against primary HIV-1 isolates than the previously characterized 17b and 
48d
161.  The sulfated-tyrosines of 412d have been localized to a conserved pocket of the 
coreceptor binding site
162.  Though CD4i antibodies target a critical epitope of gp120, 
binding to gp120 comes at a substantial entropy cost.  CD4i antibodies have some of the 
highest perturbation factors – the amount of conformational changes Env undertakes in 
order for the antibody to bind – which limit its ability to bind Env with high affinity
140.  
Efficient HIV-1 bNAbs have a low PF and bind Env with high affinity.  The high 
perturbation factor explains why CD4i antibodies are less potent than other HIV-1 
bNAbs. 
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Peptide inhibitors 
As mentioned, because Env has recessed and hidden its receptor-binding sites, 
these sites can be more readily accessed by smaller peptides, single chain variable 
fragments (scFv), or Fab (fragment antigen-binding) constructs than by full-length 
antibodies.  Vita et al. developed a CD4-mimetic peptide built from scorpion toxin 
scaffold containing CD4 residues 40-43 (QSGF)
163.  These CD4 residues target the Phe43 
pocket of the gp120 CD4-binding site.  This CD4-mimetic peptide could induce 17b 
binding, indicating that it promotes the CD4-bound state of Env
164.  Quinlan et al. created 
soft-randomized libraries of the CD4-mimetic peptide and were able to improve its 
affinity for gp120 using phage display. CD4-mim6 could neutralize HIV-1 isolates 
greater than the predecessor – CD4mim1 – but overall, was not as broad or potent as 
CD4-Ig. 
Because the sulfotyrosine-binding pockets of gp120 are smaller than the CD4-
binding cavity, the epitope can be targeted by linear peptides.  As stated above, the CDR-
H3s of numerous CD4i antibodies contain sulfated-tyrosines that mimic those found at 
the N-terminus of CCR5.  The CDR-H3 of E51 has five tyrosines modified by sulfates 
that are critical for it to bind gp120
158.  Accordingly, it was shown that a CCR5-mimetic 
(CCR5mim) based on the 15 amino-acid portion of the CDR-H3 of E51 with the Fc of 
IgG1, CCR5mim1-Ig, could bind to gp120 molecules and neutralize a panel of HIV-1 
pseudoviruses
165.  The dimer form of CCR5mim1-Ig can bind to trimeric envelope better 
than the monomer form presumably because it can bind two gp120 monomers of the Env 
trimer
109.  Newer CCR5mim peptides have been developed based on CDR-H3 of PG16 
and CCR5mim1
166.  The CDR-H3 of PG16, like most CD4i antibodies, contains sulfated 29 
 
tyrosines.  Out of seven swap variants of PG16 and CCR5mim2, two variants - pSwap3-
Ig and pSwap7-Ig (CCR5mim2-Ig) - bound gp120 and Env trimers better than 
CCR5mim1-Ig.  Like CD4i antibodies, binding of Env by CCR5mim peptides can be 
induced by sCD4 binding. 
Dual-acting inhibitors 
  New HIV-1 entry inhibitors are being developed that target multiple epitopes of 
Env.  Such inhibitors have been designed to target the receptor-binding sites on Env.  
One of these inhibitors fused sCD4 with the scFv form of 17b (sCD4-17b)
167,168.  This 
construct was able to neutralize a diverse panel of isolates covering a range of different 
clades.  Similar to that of sCD4-17b, when a double-mimetic peptide was created by 
Quinlan and Joshi et al. by fusing CD4mim6 with CCR5mim3 and expressed as an 
immunoadhesin, it could neutralize HIV-1 isolates better than CD4-Ig
169.  Both the 
sCD4-17b and double-mimetic peptide constructs have the ability to bind both receptor- 
binding sites on gp120.  Chen et al. developed similar fusion constructs (4Dm2m and 
6Dm2m) that target the receptor-binding sites by fusing a single domain form of sCD4-Ig 
with m36.4, which targets the coreceptor binding site
170.  Both 4Dm2m and 6Dm2m 
neutralized HIV-1 isolates more efficiently that VRC01.  Lu et al. engineered an effective 
bivalent HIV-1 entry inhibitor composed of sCD4 with the fusion inhibitor T1144
171.  
Similar to the previous groups, Falkenhagen et al. developed fused constructs of sCD4 
with scFV-17b or FIT45, a fusion inhibitor similar to T20
172.  Along with a tri-acting 
construct of sCD4 with scFV-17b and FIT45, these constructs could neutralize HIV-1 
isolates better than CD4-Ig and T20.  Taking a somewhat different approach, West et al. 
generated bivalent inhibitors by fusing domains 1 and 2 of CD4 to 17b, E51, and 2G12 30 
 
antibodies
173.  Again, these constructs increased the neutralization efficiencies compared 
to the original constructs. Taken together, dual-acting constructs targeting multiple 
epitopes of Env inhibit HIV-1 more efficiently than their separate components that target 
single epitopes. 
  Targeting multiple epitopes on Env can also be achieved by creating bivalent 
antibodies.  Bivalent antibodies are created through a “knobs and holes” design by 
mutating residues in the antibody Fc domain.  The knobs and holes method can achieve 
>90% heterodimer formation of bivalent antibodies in vitro
174.  Although bivalent anti-
Env antibodies have not yet been described, Pace et al. have created an antibody 
combining iMab, with the scFv forms of PG9 and PG16 (termed PG9-iMab and PG16-
iMab, respectively)
175.  iMab localizes the fused PG9 or PG16 scFv domains to CD4.  
This localization of the scFvs keeps them in close proximity to gp120 when the Env 
binds CD4.  Despite relatively lower breadth of PG9 and PG16 compared to other 
bNAbs, both PG9-iMab and PG16-iMab neutralized 100% of 118 HIV-1 isolates tested.  
The concept of targeting the HIV-1 receptors is unique and can be broadened towards 
targeting a coreceptor using an antibody like PRO 140. 
1.G.  Antibody Combinations 
  Another way of targeting multiple epitopes of Env is to combine HIV-1 
antibodies.  Early studies showed that combinations mixing CD4bs antibodies with 
antibodies directed to the V2 or V3 loops could be synergistic
176-181.  A few groups 
looked at combinations of b12, 2G12, 2F5, and 4E10
182-185, as these were the best NAbs 
available until the discovery of PG9 and PG16.  A more recent report examined a 
combination of PG9 with VRC01 and found there to be no synergy, yet it was shown that 31 
 
the antibodies could complement each other to increase their overall breadth
186.  Synergy 
was also observed between two classes of antibodies targeting the C1 and V2 regions of 
Env that were derived from vaccine recipients in the RV144 Thai trial
187.  In vivo studies 
have shown that antibody combinations are able to suppress infection in HIV-1 infected 
humanized mice
188 and SHIV infected rhesus macaques
189,190.  Further work describing 
how different classes of bNAbs work together will be critical to the development of 
antibody cocktails for therapy. 
1.H.  Summary 
  HIV-1 Env is a structurally complex viral protein that contains numerous 
obstacles hindering the development or elicitation of potent bNAbs.  HIV-1 can be more 
efficiently neutralized with fewer routes of escape by targeting multiple conserved 
epitopes on Env with HIV-1 bNAbs or peptide inhibitors.  In the following chapters, we 
will explore the utility of targeting the CD4- and coreceptor-binding site simultaneously.  
In Chapter 2, we demonstrate that we can achieve more potent neutralization with 
combinations of CD4-Ig and CCR5mim2-Ig or CD4bs antibodies with CD4i antibodies.  
In Chapter 3, we characterize a newly developed HIV-1 entry inhibitor that fuses 
CCR5mim1 to the C-terminus of CD4-Ig.  In Chapter 4, we discuss our findings in the 
context of current efforts to develop antibody-based therapeutics or an HIV-1 vaccine. 
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CHAPTER 2 
 
Combinations of HIV-1 Entry Inhibitors that Target the CD4-  
and Coreceptor-Binding Sites Efficiently Neutralize HIV-1 Isolates 
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2.A. Abstract 
The HIV-1 envelope glycoprotein (Env) is a trimer of gp120/gp41 heterodimers 
that mediates viral entry.  Env binds cellular CD4, an association which stabilizes a 
conformation favorable to its subsequent association with a coreceptor, typically CCR5 
or CXCR4.  The CD4- and coreceptor-binding sites serve as epitopes for two classes of 
HIV-1 neutralizing antibodies – CD4 binding site (CD4bs) and CD4-induced (CD4i) 
antibodies, respectively.  Here we observed that, at a fixed total concentration, mixtures 
of the CD4i antibody E51 and the CD4bs antibody VRC01 neutralized the HIV-1 isolates 
ADA and 89.6 more efficiently than either antibody alone.  Using a wider range of 
isolates, we found that E51 promoted association of four CD4bs antibodies to the Env 
trimer, but not to monomeric gp120.  Interestingly, and in contrast to CD4-Ig, the 
relationship is not reciprocal: CD4bs antibodies do not efficiently promote E51 binding to 
Env trimer.  Consistent with these observations, CD4-Ig, but none of the CD4bs 
antibodies tested, substantially increased HIV-1 infection of a CD4-negative, CCR5-
positive cell line.  We conclude that E51 and VRC01 are more potent together largely 
because E51 promotes access of VRC01 to the Env trimer.  Our data also suggest that 
potent CD4bs antibodies avoid inducing Env conformations that bind E51 or CCR5. 
2.B. Introduction 
Human immunodefeciency virus type 1 (HIV-1) uses its envelope glycoprotein 
(Env) to gain entry into host cells.  Env is synthesized as precursor gp160 proteins which 
assemble as trimers before they are cleaved into gp120 and gp41 subunits
191.  The gp120 
subunit binds the primary HIV-1 receptor, CD4
16-18, which then induces tertiary and 
quaternary conformational changes in Env that promote association with a coreceptor, 35 
 
usually CCR5 or CXCR4
28,31.  The CD4- and coreceptor-binding sites are the two most 
conserved regions of gp120
20,21.  Two classes of antibodies, corresponding to these 
regions have been defined: CD4-binding site (CD4bs) antibodies, and CD4-induced 
(CD4i) antibodies.  The latter are so named because CD4 binding induces a conformation 
that promoters their association with gp120.  
The antibody b12, isolated from a patient library by phage display, was the first 
potent CD4bs antibody described
134.  However, its breadth was limited to 35% against a 
broad panel of HIV-1 isolates
136.  More recently, broader and more potent antibodies 
have been identified, notably VRC01, 3BNC117, and NIH45-46
136,137,142.  These 
antibodies neutralize more than 90% of HIV-1 isolates assayed.  The breadth and potency 
of NIH45-46 was increased through both a G54W mutation – the added tryptophan 
targeting a cavity in the CD4-binding site of gp120 occupied by phenylalanine 43 of CD4 
- and through additional light-chain modifications
144,145.  These highly potent broadly 
neutralizing antibodies (bNAbs) can protect from HIV-1 challenge and reduce viral loads 
in infected humanized mice and rhesus macaques
188-190,192. 
Relative to CD4bs antibodies, well characterized CD4i antibodies like 17b and 
48d, are substantially less broad and potent
157,193,194.  This inefficiency is largely a 
consequence of their recognition of an Env conformation usually unavailable in the 
absence of CD4, coinciding with the inaccessibility of their epitope to antibody-sized 
molecules due to the proximity of the viral and cellular membranes
93.  Some CD4i 
antibodies, including E51 and 412d, mimic CCR5 by incorporating sulfotyrosines into 
their heavy-chain CDR3 regions
89,158.  These sulfotyrosines bind highly conserved 
pockets on gp120 that recognize the CCR5 amino-terminus.  Perhaps as a consequence, 36 
 
E51 and 412d typically bind Env and neutralize HIV-1 more efficiently than 17b or 48d.  
The structure of gp120 in complex with 412d localizes two sulfotyrosine binding pockets 
at the base of the third variable loop and in the fourth conserved domain
92. 
Because CD4 and CD4i antibodies bind the envelope glycoprotein cooperatively, 
we explored the relationship between the CD4i antibody E51 and a panel of CD4bs 
bNAbs.  We first showed that we could get greater neutralization of four HIV-1 isolates 
when targeting the receptor-binding sites with CD4-Ig and CCR5mim2-Ig.  We then 
observed that, at the same total concentrations, mixtures of E51 and the CD4bs antibody 
VRC01 were more potent than either antibody alone.  However, unlike CD4-Ig, CD4bs 
antibodies did not promote E51 binding to the Env trimer.  Consistent with this 
observation, CD4-Ig, but not CD4bs antibodies, could promote infection of CCR5-
positive, CD4-negative cells.  In contrast, E51 promoted quaternary changes in Env that 
increased its binding to several highly potent CD4bs antibodies, including VRC01.  Thus, 
CD4i antibodies can enhance the potency of CD4bs antibodies, presumably by increasing 
access to the CD4-binding site. 
2.C. Materials and Methods 
Cells and plasmids.  All cell lines were grown in DMEM with 10% fetal bovine serum 
at 37°C.  TZM-bl cells were obtained through the NIH AIDS Reagent Program, Division 
of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc
195-
199.  Cf2-Th CCR5-positive, CD4-negative cells were provided by Dr. Hyeryun Choe.  
The variable heavy and light chains of E51 were cloned into human and murine IgG1 
expression vectors.  89.6, ADA, JRFL, SA32, and ConC gp160 expression vectors have 
been previously described
109,166.  89.6, ADA, SA32, and ConC gp160-Δcytoplasmic tail 37 
 
expression vectors have been previously described
166.   pNL4-3.luc.R
-.E
- was obtained 
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. 
Nathaniel Landau
200,201.  CD4-Ig has been previously described
166.  Vectors expressing 
VRC01 heavy and light chains were obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH from Dr. John Mascola
136,202.  10E8 expression vectors 
were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH 
from Dr. Mark Conners
152.  Purified b12 and 2G12 antibodies were obtained from 
Polymun Scientific.  Vectors expressing NIH45-46 and 3BNC117 were provided by Dr. 
Michel Nussenzweig.  The NIH45-46
G54W heavy-chain expression vector was provided 
by Dr. Pamela Bjorkman. 
Antibody and CD4-Ig production and purification.  HEK293T cells (ATCC) seeded 
in T-175 flasks (Falcon) were co-transfected with 40 µg of both heavy chain vector and 
light chain vector per flask of the antibodies VRC01, NIH45-46, NIH45-46W, 3BNC117, 
E51, 10E8 or with 80 µg per flask CD4-Ig vector with Calcium Phosphate transfection kit 
(Clonetech).  At 12-16 hours post transfection, cells were washed with PBS and grown in 
FreeStyle 293 medium (Invitrogen).  48 hours post-transfection, medium was collected, 
centrifuged, and filtered with a 0.45 µm filter flask (Millipore).  Protein A sepharose 
beads (GE Healthcare) and Complete protease inhibitor cocktail (Roche) were added to 
the medium and agitated overnight at 4°C.  Beads were collected in a gravity flow 
through column (Bio-Rad), washed once with 0.5M NaCl in PBS, washed once with 
PBS, and eluted with IgG Elution Buffer (Thermo Scientific) into 1M Tris-HCl Buffer, 
pH 9.0 (G Biosciences).  Buffer was exchanged with PBS and protein concentrated to 1 38 
 
mg/mL with Amicon Ultura Centrifugation Filters (Millipore).  Antibodies were stored at 
4ºC.  
TZM-bl neutralization assays.  Pseudotyped HIV-1 was produced by co-expression of 
envelope glycoproteins of the indicated HIV-1 isolates with NL4-3ΔEnv, an HIV-1 
expression vector lacking a functional env gene.  293T cells, grown to 50% confluency in 
T175 (Falcon) flasks, were transfected with 25 µg of plasmid encoding envelope 
glycoprotein, 45 µg of NL4-3ΔEnv, and 5 µg each of plasmids expressing the HIV-1 tat 
and rev genes, by the calcium phosphate technique.  10% FBS-DMEM was changed at 12 
h, and medium was collected at 48 h.  Viral supernatants were cleared by centrifugation 
for 10 min at 1500 × g, passed through a 0.45-µm syringe filter (Millipore), and stored at 
-80 °C. 
TZM-bl neutralization assays were performed as previously described
203.  Briefly, HIV-1 
pseudoviruses were pre-incubated with titrated amounts of antibody or CD4-Ig in DMEM 
(10% FBS) for 1 hour at 37°C.  TZM-bl cells were detached by trypsinization and diluted 
in DMEM (10% FBS) to 100,000 cells/mL and added to the pseudovirus/inhibitor 
mixture.  Cells were then incubated for 48 hours at 37°C.  Viral entry was analyzed using 
Britelite Plus (Perkin Elmer) and luciferase was measured using a Victor X3 plate reader 
(Perkin Elmer).  Combination Index (CI) values for 50% inhibition (CI50) to determine 
synergy were calculated as previously described
204-207. 
GHOST cell neutralization assay.  GHOST-CCR5 or –CXCR4 cells were plated into 
12-well plates at 50,000 cells per well.  HIV-1 pseudovirus was diluted in RPMI and 
titrated amounts of CCR5mim2-Ig, pSwap3-Ig, CCR5mim1-Ig, and pCa5R-Ig were 
added.  Virus and inhibitor were incubated at room temperature for 20 minutes and added 39 
 
to the cells for 2 hours at 37°C.  Cells were then washed with serum free medium and 
then incubated in 1 mL of DMEM (10% FBS) for 48 hours at 37°C.  Cells were then 
trypsinized and resuspended in PBS (2% FBS), pelleted, and resuspended in a fixative 
solution (1% paraformaldehyde in PBS).  Viral entry was determined by flow cytometry 
based on GFP expression. 
ELISA studies of monomeric HIV-1 gp120.  ELISA plates (Costar) were coated with 5 
µg/mL HIV-1 gp120 (Immune Technolog Corp.) overnight at 4°C.  Plates were washed 
with PBS-T (PBS + 0.05% Tween-20) twice and blocked with 5% milk in PBS for 1 hour 
at 37°C.  Dilutions of murine-E51, CD4-Ig or CD4bs antibodies blocked with 5% milk in 
PBS were added to the plate and incubated for 1 hour at 37°C.  Samples were washed 
five times with PBS-T and fixed concentrations of CD4-Ig or CD4bs antibodies (in the 
case of samples pre-incubated with murine-E51) or murine-E51 (in the case of samples 
pre-incubated with CD4-Ig or CD4bs antibodies) were added.  Plates were incubated for 
1 hour at 37°C.  Samples were washed five times with PBS-T and labeled with a 
horseradish peroxidase-conjugated secondary antibody (Jackson Immuno Research) 
recognizing human IgG1.  Plates were incubated for 1 hour at 37°C and then washed ten 
times with PBS-T.  TMB solution (Fisher) was added for 10 minutes at room temperature 
and then stopped with TMB Stop Solution (Southern Biotech).  Absorbance was 
measured at 450 nm by a Victor X3 plate reader (Perkin Elmer). 
Flow cytometric analysis of cell-expressed envelope glycoprotein trimers  HEK293T 
cells were transfected with plasmids expressing the indicated envelope glycoproteins 
lacking cytopasmic residues 732 to 876 (HXBc2 numbering) together with plasmid 
encoding the tat protein.  Transfection medium was replaced after an overnight 40 
 
incubation and cells were harvested 48 hours post-transfection.  Harvested cells were 
washed twice in flow cytometry buffer (PBS with 2% goat serum, 0.01% sodium azide).  
Cells were incubated with serially diluted CD4bs antibody, CD4-Ig, or murine-E51 on ice 
for 1 hour and then washed twice with flow cytometry buffer.  If cells were pre-incubated 
with murine-E51, cells were then incubated with a 10 ng/mL of CD4bs antibody or CD4-
Ig on ice for 1 hour.  If cells were pre-incubated with CD4bs antibodies or CD4-Ig, cells 
were then incubated with 25 ng/mL murine E51 on ice for 1 hour.  After incubation, cells 
were washed twice with flow cytometry buffer.  APC or FITC-labeled secondary 
antibodies recognizing human or murine Fc (Jackson Immuno Research), respectively, 
were incubated with cells for 30 minutes.  Cells were washed twice with flow cytometry 
buffer, twice with PBS, and resuspended in 1% paraformaldehyde solution.  Binding was 
analyzed with an Accuri C6 Flow Cytometer (BD Biosciences) and data was analyzed 
with the C6 Software (BD Biosciences). 
Infection of CD4-negative cells.  HIV-1 pseudovirus expressing firefly luciferase was 
pre-incubated with titrated amounts of antibodies or CD4-Ig in DMEM (10% FBS) for 1 
hour at 37°C.  CD4-negative Cf2Th-CCR5 cells were harvested and diluted in DMEM 
(10% FBS) to 100,000 cells/mL and added to the pseudovirus/inhibitor mixture.  Cells 
were then incubated for 48 hours at 37°C.  Viral entry was analyzed using Britelite Plus 
(Perkin Elmer) and luciferase was measured by a Victor X3 plate reader (Perkin Elmer). 
2.D. Results 
Mixtures of CD4-Ig and CCR5mim2-Ig neutralize HIV-1 isolates more efficiently 
than either inhibitor alone.  Having shown that new CCR5mim peptides bind Env, we 
wanted to test their ability to neutralize HIV-1 isolates.  We analyzed pC5aR-Ig, 41 
 
CCR5mim1-Ig, pSwap3-Ig, and CCR5mim2-Ig using a previously described entry 
inhibition assay. Both pSwap3-Ig and CCR5mim2-Ig neutralized the dualtropic, clade B 
isolate 89.6 more efficiently than CCR5mim1-Ig, with 50% inhibitory concentrations 
(IC50s) of approximately 10 nM. They also neutralized consensus B and C isolates more 
efficiently, but with IC50s of approximately 4 µM.  In an effort to show that targeting the 
minimum receptor binding epitopes would be more efficient than targeting either epitope 
alone, we next investigated the ability of CCR5mim2-Ig to enhance CD4-Ig-mediated 
neutralization of HIV-1. When total protein was kept constant at the IC50 of CD4-Ig 
alone, a 9:1 ratio of CD4-Ig to CCR5mim2-Ig (4.5:1 on a molar basis) neutralized all 
pseudoviruses assayed more efficiently than CD4-Ig alone. This effect was evident at a 
9:1 ratio for a range of total protein concentrations, more so for the neutralization 
sensitive SG3 isolate. 
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Figure 2.1.  CCR5mim2-Ig synergizes with CD4-Ig to neutralize HIV-1 infection. (A) The inhibitory 
activities of the indicated peptide-Fc fusions were measured with a TZM-bl neutralization assay using the 
envelope glycoprotein of the dualtropic clade B isolate 89.6. Infectivity is represented as a percentage of 
luciferase activity in the absence of inhibitor. (B) The indicated peptide-Fc fusions were assayed for their 
ability to limit infection of retroviruses pseudotyped with consensus B and C envelope glycoproteins in 
GHOST-CCR5 cells. Infection was measured as green fluorescent protein (GFP) activity by flow 
cytometry. (C) Relative infection of HIV-1 pseudotyped with the indicated envelope glycoproteins was 
measured with a TZM-bl neutralization assay in the presence of various ratios of CD4-Ig and CCR5mim2-
Ig in which the total amount of protein was held constant. Horizontal axis indicates percentage of 
CCR5mim2-Ig. The total amount of protein for each isolate was chosen to be approximately that of the 
IC50 of CD4-Ig alone: 89.6 (clade B, R5X4), 50 ng/ml;ADA(clade B, R5), 40 ng/ml; SA32 (clade C, R5), 
75 ng/ml; and consensus C (clade C, R5), 4 µg/ml. (D) A TZM-bl cell neutralization assay was performed 
at various concentrations of CD4-Ig and CCR5mim-Ig at a 9:1 ratio. The figure shows infection of cells 
with the SA32 (clade C, R5) and SG3 (clade B, X4) pseudoviruses in the presence of the CD4-Ig or CD4-
Ig/peptide-Ig mixtures at various concentrations. 
 
Mixtures of E51 and VRC01 neutralize HIV-1 more efficiently than either antibody 
alone.  Having shown we can get greater neutralization through mixtures of CD4-Ig and 
CCR5mim2-Ig in Figure 2.1C-D, we sought to determine whether an approach using 
HIV-1 antibodies would yield a similar result. We chose to study the CD4-binding site 43 
 
antibody VRC01 and the CD4i antibody E51, because they have similar potencies against 
a number of clade B HIV-1 isolates.  Fixing the total antibody concentration, we 
measured neutralization of HIV-1 using varying antibody ratios.  We observed that 80:20, 
60:40, and 50:50 ratios of VRC01 to E51 more potently neutralized the HIV-1 isolates 
89.6 and ADA than either antibody alone (Figure 2.2A).  A 50:50 ratio of these 
antibodies also neutralized the ADA isolate more efficiently than either antibody across 
several concentrations between 0.08 and 2 µg/ml (Figure 2.2B).  Similar mixtures of the 
CD4bs antibody b12 with E51, or of the glycosylation-dependent antibody 2G12 with 
VRC01 were assayed in parallel.  These antibody mixtures did not outperform the more 
potent antibody at any concentration (Figs. 2.2C-D).  Chou-Talalay analysis indicated 
that the Combination Index at 50% neutralization (CI50) for VRC01/E51 mixture was 
0.54, indicating that this combination was synergistic.  b12/E51 and VRC01/2G12 
mixtures yielded CI50 values greater than 1.0, indicating that these antibody mixture 
exhibited no synergy.  Thus, under some conditions and with some HIV-1 isolates, 
synergy between E51 and VRC01 can be observed.  Note however, that mixtures of E51 
with the CD4bs antibodies NIH45-46 or 3BNC117 neutralized less efficiently than either 
CD4bs antibody alone, due to their greater potency relative to E51 (not shown).   44 
 
 
Figure 2.2.  In vitro neutralization by combinations of CD4bs antibodies with E51.  (A) HIV-1 isolates 
89.6 and ADA were pre-incubated for 1h with a fixed concentration (0.3 µg/mL) but varying ratios of 
VRC01:E51 mixtures.  TZM-bl cells were then added and incubated for 48h.  Infection was measured by 
the percentage luciferase expression in the absence of inhibitor.  (B) Similar set up as (A) except HIV-1 
isolate ADA was pre-incubated with varying concentrations of VRC01, E51, or a 50:50 mixture of VRC01 
and E51. The dashed line indicates the fixed concentration used in (A).  (C) Similar set up as (B) except 
HIV-1 isolate ADA was pre-incubated with varying concentrations of b12, E51, or a 50:50 mixture of b12 
and E51. (D) Similar set up as (B) except HIV-1 isolate ADA was pre-incubated with varying 
concentrations of VRC01, 2G12, or a 50:50 mixture of VRC01 and 2G12. 
E51 does not enhance CD4bs antibody binding to monomeric gp120.  To understand 
the mechanism by which VRC01 and E51 combine to more potently neutralize ADA and 
89.6, we sought to determine whether either antibody enhanced association of the other to 
gp120 monomers and to cell expressed Env trimers.  We first examined by ELISA 
whether binding of E51 to immobilized gp120 was improved in the presence of 
increasing amounts of four CD4bs bNAbs or the CD4bs antibody b12, whose epitope 
extends into a region proximal to the E51 epitope.  To distinguish E51 from CD4bs 45 
 
antibodies, its Fc region was exchanged with that of murine IgG1, and anti-human or 
anti-murine secondary antibodies were used to detect CD4bs antibodies and E51 binding, 
respectively.  As expected, CD4-Ig consistently enhanced E51 binding, while b12 
inhibited E51 binding, to all three gp120 proteins tested.  The ability of the CD4bs 
bNAbs to promote E51 association was isolate and antibody dependent.  Specifically, 
VRC01 and NIH45-46
G54W, but not NIH45-46 or 3BNC117, enhanced binding of E51 to 
clade B gp120 proteins, but not to a consensus clade C (ConC) gp120 (Figure 2.3A).  We 
also assayed the ability of E51 to promote gp120 association with each of these 
antibodies.  In general, E51 had little effect on most of these antibodies, but did promote 
CD4-Ig association with ADA gp120, and VRC01 association with ConC gp120 (Figure 
2.3B).  Thus, for clade B isolates, VRC01 modestly enhanced E51 association with 
gp120 monomers, but E51 had no effect on VRC01 binding to these monomers. 
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Figure 2.3.  Promotion of gp120 monomeric association by CD4bs antibodies and E51.  (A) ELISA 
plates were coated with 5 µg/mL of indicated gp120 molecules.  Immoblized gp120 was pre-incubated with 
serially diluted CD4-Ig or CD4bs antibodies as indicated starting at 50 µg/mL.  Wells were washed and 
incubated with a constant amount of E51.  Binding of E51 was measured by absorbance of an anti-HRP 
secondary antibody recognizing murine-Fc at 450 nm and data was normalized to E51 binding without pre-
incubation of CD4-Ig or CD4bs antibody.  (B) Similar experiment as (A) except gp120 molecules indicated 
were pre-incubated with serially diluted E51 starting at 50 µg/mL.  Wells were washed and incubated with 
a constant concentration CD4-Ig or indicated CD4bs antibody.  Data was analyzed same as in (A) except 
normalized to binding of CD4-Ig or CD4bs without E51 pre-incubation. 
E51 enhances binding of CD4bs bNAbs to cell-surface expressed Env trimers.  We 
next explored whether changes in the quaternary structure of Env may be more relevant 
to the synergy observed in Figure 2.2A-B.  Using flow cytometry, we examined the 
ability of E51 to bind Env trimers expressed on the surface of HEK293T cells in the 
presence of increasing amounts of CD4bs antibodies pre-bound to Env (Figure 2.4A).  
We observed that, at varying concentrations, CD4-Ig could promote binding of E51 to 
Env, but that no CD4bs bNAb did so efficiently.  b12 interfered with E51 binding to Env 
as it did with monomeric gp120.   Surprisingly, and in contrast, varying concentrations of 
E51 enhanced binding of all four CD4bs bNAbs to Env, but had only very modest effects 47 
 
on CD4-Ig or b12 (Figure 2.4B).  We conclude that E51 facilitates binding of VRC01 and 
other CD4bs bNAbs to the Env trimer, but that, unlike CD4-Ig, CD4bs bNAbs do not 
increase binding of E51.  Taken together with the monomeric gp120 ELISA data (Figure 
2.3), we conclude that E51 induces quaternary conformations in Env favorable to its 
association with CD4bs bNAbs.  Finally, we infer that the synergy observed in Figure 2 
is largely due to the ability of E51 to promote these quaternary conformations. 48 
 
 
Figure 2.4.  Promotion of E51 or CD4bs antibody association to trimeric HIV-1 Env.  (A) HEK293T 
cells were transfected to express indicated envelope glycoproteins that lack a portion of the cytoplasmic 
domain.  Cells were pre-incubated with concentrations of CD4-Ig and indicated antibodies at 50 µg/mL and 
serially diluted by 5-fold to 0.4 µg/mL.  Cells were washed and then incubated with 0.25 µg/mL E51.  
Binding was analyzed by flow cytometry.  Mean fluorescent intensity (MFI) data are normalized to value 
of E51 binding without CD4-Ig or CD4bs antibodies pre-bound.  (B) Similar experiment as (A) except cells 
were pre-incubated with E51 at serially diluted concentrations starting at 50 µg/mL.  Cells were washed 
and then incubated with 0.01 µ g/mL of indicated antibody or CD4-Ig.  Analysis was performed same as 
(A) except MFI data were normalized to the value of each antibody or CD4-Ig binding without E51 pre-
incubation. 49 
 
Unlike CD4-Ig, CD4bs bNAbs do not promote HIV-1 infection of CD4-negative 
cells.  As shown in Figure 2.4, CD4-Ig clearly behaves differently from CD4bs bNAbs.  
It promotes E51 association to Env trimers but its own association with Env is largely 
unaffected by the presence of E51.  In contrast, CD4bs bNAbs do not significantly 
improve E51 binding to Env, but E51 promotes association of CD4bs bNAbs.  To 
determine if these differences had functional consequences, we incubated five HIV-1 
isolates with CCR5-positive, CD4-negative Cf2Th cells in the presence of CD4-Ig or 
CD4bs bNAbs (Figure 2.5).  As expected, CD4-Ig substantially enhanced infection of 
these cells, with maximum enhancement peaking at 0.1-1 µg/ml.  In contrast, little or no 
enhancement of infection was observed with CD4bs bNAbs antibodies, or with the 
neutralizing antibodies b12, 2G12, or 10E8.  Thus the inability of CD4bs bNAbs to 
promote E51 association is consistent with their corresponding inability to promote 
infection of CCR5-positive cells when cellular CD4 is limiting or absent.  We infer that, 
unlike CD4-Ig, these antibodies do not promote binding of viral Env to CCR5.  50 
 
 
Figure 2.5.  Enhancement of HIV-1 entry into Cf2Th CCR5+/CD4- cells by CD4bs antibodies.  
Luciferase-expressing HIV-1 pseudotyped with the indicated Env was pre-incubated with the antibodies 
indicated.  Dog thymus Cf2Th cells expressing CCR5, but not CD4, were added to the virus-antibody 
mixture and incubated for 48 hrs.  Infection was measured by the percentage luciferase expression in the 
absence of inhibitor. 
2.E. Discussion 
Here we observed a modest synergy in two cases when targeting the HIV-1 
receptor-binding sites: in one instance CD4-Ig and CCR5mim2-Ig was combined and in a 
second case, mixtures of the CD4bs antibody VRC01 and the CD4i antibody E51 were 
assayed.  In an effort to understand the basis of this synergy, we studied how E51 
interacts with several VRC01-like bNAbs antibodies, as well as the CD4bs antibody b12.  
We observed with monomeric gp120 that CD4-Ig induced a conformation preferred by 
E51, but in general VRC01-like bNAbs did so less efficiently.  Differences between 
CD4-Ig and VRC01-like antibodies were more pronounced with cell-expressed trimeric 
Env.  CD4-Ig robustly enhanced E51 binding to Env trimers (Figure 2.6A), but VRC01-51 
 
like antibodies were much less efficient in promoting E51 binding (Figure 2.6B).  
Consistent with this observation, CD4-Ig, but not CD4bs antibodies enhanced HIV-1 
infection of a CD4-negative, CCR5-positive cell line.  
 
FIG 2.6. Model of Env induction by E51 and CD4bs antibodies.  Shown is the model for induction that 
combines our data with the findings of Kwong et al. [Ref. 109], Tran et al. [Ref. 22], and Bartesaghi et al. 
[Ref. 23].  The unbound trimeric Env starts in a closed conformation (left).  (A) When CD4 (or soluble 
CD4, CD4-Ig) binds Env, the conformation is opened [Ref. 22].  This conformation promotes CD4i 
binding, like E51 or 17b, both on monomeric gp120 and trimeric Env.  (B) In contrast, the binding of a 
CD4bs antibody (VRC01, NIH45-46, etc.) keeps the conformation in a closed state [Ref. 23].  Though this 
is the case, these antibodies have the ability to moderately promote CD4i binding on monomeric gp120 as 
seen in Figure 2.3A and described in Scheid et al.
137 (C) Like CD4, when E51 (or other coreceptor 
inhibitors like 17b, m6, CCR5mim1-Ig, etc.) bind Env, the Env conformation opens [Ref. 22, 22, 109].  
This conformation induces CD4bs antibody binding on trimeric Env, but not monomeric gp120 as seen in 
Figure 2.4B and Figure 2.5B, respectively. 
  
The most striking difference, however, between CD4-Ig and CD4bs bNAbs was 
their ability to bind trimeric Env in the presence or absence of E51.  E51 had almost no 52 
 
effect on the ability of CD4-Ig to bind trimers.  In contrast, E51 markedly enhanced Env 
binding of VRC01, NIH45-46, NIH45-46
G54W, and to a lesser extent 3BNC117 (Figure 
2.6C).  This effect was not observed with gp120 monomers.  We therefore infer that E51 
can promote or stabilize quaternary conformational changes in Env that facilitate access 
of CD4bs bNAbs.  The quaternary changes do not affect CD4-Ig binding and, indeed, are 
likely induced by CD4-Ig binding.  These functional observations are consistent with 
cryo-electron microscopy studies by Tran et al. who observed that the CD4i antibody 
17b, but not VRC01, induced an open conformation in Env
22.  When a mixture of VRC01 
and 17b was added to Env, the conformation was open.  The current study makes clear 
that CD4bs bNAbs preferentially bind this open conformation.  Bartesaghi et al. show 
that in the open conformation of Env, the variable loops of Env are shifted in a way that 
further exposes the Env’s CD4-binding site, as well as, presumably, the coreceptor 
binding site
23.  The CDR-H3 of E51 is a close mimic of CCR5, so it is not surprising that 
E51 preferentially binds and induces or stabilizes this open conformation.   
This study also highlights other differences between CD4-Ig and VRC01-class 
bNAbs.  As mentioned, CD4-Ig more efficiently promotes E51 binding to monomeric 
gp120 and trimeric Env.  This difference may be a necessary property of potent CD4bs 
antibodies for two possible reasons.  First, an antibody selected for potency would not be 
expected to promote infection at low concentrations or when cellular CD4 was limiting.  
Second, there is likely to be an energy and/or an entropy barrier limiting access to the 
open conformation.  If an antibody can avoid the free energy penalty of inducing this 
conformation, it can bind with greater affinity
140.  In contrast, cellular CD4 and therefore 
CD4-Ig must necessarily pay this penalty to facilitate coreceptor binding.  CD4i 53 
 
antibodies, which bind gp120 and Env similarly to CCR5, must also pay this penalty, 
perhaps explaining the lower potency of these antibodies relative to CD4bs bNAbs.  Of 
course, when Env is bound to CD4, this energetic cost is paid, and CD4i antibodies bind 
efficiently. 
We show here that the synergy between VRC01 and E51 is likely the result of the 
ability of E51 to induce the open state, and facilitate access to the CD4-binding site.  
Highly potent VRC01-like bNAbs are rare.  Most CD4bs antibodies in the sera of 
infected individuals neutralize Env less efficiently, in part because they cannot access 
their epitopes on the closed Env trimer and in part because they pay an energetic price for 
inducing the CD4-bound state on Env.  Weaker CD4bs antibodies F105, b6, and b13 
have been shown to have a high perturbation factor on Env which has the consequence of 
being less reactive towards a broad range of HIV-1 isolates
140.  Thus the presence of 
relatively potent CD4i antibodies in the sera might complement both limitations of these 
less potent CD4bs antibodies.  It is further possible that CD4i antibodies, by promoting 
exposure to the CD4-binding site, might enhance the generation of more potent CD4bs 
antibodies.  It may therefore be useful to elicit CD4i antibodies as part of a stepwise 
effort to elicit VRC01-class antibodies, or to enhance the potency of less efficient CD4bs 
antibodies. 
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CHAPTER 3 
 A CCR5-mimetic Sulfopeptide Converts CD4-Ig to an Exceptionally  
Broad and Potent Inhibitor of HIV-1 Entry 
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3.A. Abstract 
Soluble CD4 and its more bioavailable form, CD4-Ig, neutralize HIV-1 less 
potently than many broadly neutralizing antibodies (bNAbs) because they bind the HIV-1 
envelope glycoprotein with lower affinity, and they promote infection when cellular CD4 
is limiting.  Here we show that a fusion of CD4-Ig with a small CCR5-mimetic 
sulfopeptide (eCD4-Ig) overcomes both of these shortcomings: eCD4-Ig bound the 
envelope glycoprotein with high avidity and its sulfopeptide inhibited infection promoted 
by CD4-Ig.  eCD4-Ig efficiently neutralized a diverse panel of antibody-resistant tier 2 
and tier 3 HIV-1 isolates without exception and with IC50s ranging from 0.002 to 1.137 
µg/ml (0.02-11 nM) − values comparable to or better than those of the best HIV-1 
bNAbs.  Because it binds only conserved regions of the HIV-1 envelope glycoprotein, it 
is also broader than any bNab.  Underscoring this breadth, eCD4-Ig potently neutralized 
HIV-2 and antibody-resistant SIV isolates, as well as a comprehensive panel of 38 HIV-1 
isolates resistant to the current best CD4-binding site (CD4bs) bNAbs.  Further, eCD4-Ig 
induced markedly more efficient antibody-dependent killing of HIV-1- or SIV-infected 
cells than did CD4-Ig.  Finally, eCD4-Ig retained its efficacy in vivo: it protected 
humanized mice from a high-dose HIV-1 challenge, and a rhesus macaque analogue 
could be expressed to peak levels greater than 100 µg/ml in three of four macaques 
inoculated with an adeno-associated virus (AAV) vector.  eCD4-Ig is thus a highly 
potent, exceptionally broad and mechanistically distinct inhibitor of HIV-1 entry with the 
potential to prevent or treat an HIV-1 infection. 
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3.B. Introduction 
Entry of the human immunodeficiency virus type 1 (HIV-1) requires the cell-
surface expression of CD4
16-18 and a coreceptor, principally CCR5 or CXCR4
28,31.  
CCR5-using (R5) viruses predominate in the early years of an untreated infection.  
Coincident with declining immune function, viruses sometimes emerge that utilize 
CXCR4, either in addition to CCR5 (R5X4 isolates) or alone (X4 isolates).  Association 
of the HIV-1 envelope glycoprotein gp120 with CD4 promotes its subsequent association 
with CCR5 or CXCR4
208,209.  The CCR5 amino terminus contains sulfotyrosines critical 
for this association
89.  Some CD4-induced (CD4i) HIV-1 neutralizing antibodies, for 
example E51 and 412d, are similarly sulfated in their heavy-chain CDR3 regions, and the 
sulfotyrosines of these antibodies bind the same highly conserved coreceptor-binding 
region of gp120 as the CCR5 N-terminus
92,158.  Envelope glycoproteins of R5X4 and X4 
isolates also retain these sulfotyrosine-binding pockets and are efficiently recognized by 
tyrosine-sulfated CD4i antibodies
158.   
We have previously shown that a 15-amino acid sulfopeptide homologous to the 
CCR5 amino terminus and derived from heavy-chain CDR3 region of the CD4i antibody 
E51 (CCR5mim1), bound gp120 proteins of a range of R5, R5X4 and X4 isolates, even 
in the absence of CD4
165.  CCR5mim1 bound gp120 and neutralized HIV-1 more 
efficiently than sulfopeptides based directly on CCR5
165.  Like CCR5 and tyrosine-
sulfated CD4i antibodies, binding of CCR5mim1 to the HIV-1 envelope glycoprotein was 
dependent on residues that compose the gp120 sulfotyrosine-binding pockets and was 
enhanced by soluble CD4 (sCD4).  Unlike most CD4i or CD4-binding site (CD4bs) 58 
 
antibodies, however, Fc-dimerized forms of CCR5mim1 (CCR5mim1-Ig) can bind two 
gp120 monomers of the HIV-1 envelope glycoprotein trimer. 
Soluble forms of CD4 have been extensively studied as potential 
therapeutics
210,211.  Soluble CD4 and the more bioavailable immunoadhesin, CD4-Ig, 
bind gp120 of all HIV-1 isolates, can irreversibly inactivate the HIV-1 envelope 
glycoprotein, and are demonstrated to be safe for use in humans
212,213.  However, the 
affinity of CD4 for gp120 is lower than that of efficient neutralizing antibodies
214.  In 
addition, the neutralizing potency of CD4-Ig is further reduced by its parallel ability to 
enhance infection by promoting direct association with CCR5 or other coreceptors
211,215.  
This effect is most visible at low concentrations or when cell-expressed CD4 is limiting, 
but it likely attenuates the potency of CD4-Ig at most concentrations and conditions. 
In recent years, a number of highly potent broadly neutralizing antibodies 
(bNAbs) have been characterized including, among others, the CD4-binding site (CD4bs) 
bNAbs VRC01, PGV-04, NIH45-46, and 3BNC117 (reviewed in 
216).  These antibodies 
can be used to protect humanized mice from infection, and can suppress replication of 
specific simian-human immunodeficiency viruses (SHIV) in macaques
188-190.  They bind 
Env with high affinity and typically do not promote infection at lower concentrations.  
However their epitopes are invariably larger than the receptor-binding domain of Env, 
and include variable residues that limit antibody breadth and permit escape of the virus 
without loss of fitness
142,188.  These antibodies also are extensively hypermutated and 
include multiple T- and B-cell epitopes that can be recognized as non-self
217.  Both 
properties limit their utility as therapeutics or in long-term prophylaxis strategies. 59 
 
Here we show that a fusion of CD4-Ig and CCR5mim1 binds the Env trimer 
cooperatively and with high avidity.  This fusion, eCD4-Ig, simultaneously occludes the 
CCR5-binding sites of two gp120 monomers as well as the CD4-binding site of one of 
these monomers, inhibiting the ability of CD4 to promote infection.  Moreover, it is at 
least as potent as the best neutralizing antibodies, is broader than any bNAb or entry 
inhibitor described to date, and, as we discuss, has additional properties that make it 
useful as a complement to current anti-retroviral therapies, or as part of an alternative 
vaccine. 
3.C.  Materials and Methods 
Plasmids and Cells.  Plasmid expressing CD4-Ig was previously described
218.  Fusion 
constructs were created by adding sequence encoding CCR5mim1 and tetra-glycine 
linker to N-terminus (fusion1) or between domain 2 and human Fc (fusion2) of CD4-Ig 
by inverse PCR.  eCD4-Ig and eCD4-Ig
mim2 were created by adding sequence encoding a 
tetra-glycine linker and CCR5mim1 or CCR5mim2, respectively, to the C-terminus of 
CD4-Ig by inverse PCR.  Glutamine 40 to alanine mutations were generated in eCD4-Ig 
and eCD4-Ig
mim2 mutants by Quickchange PCR.  The following reagent was obtained 
through the NIH AIDS Reagent Program (Division of AIDS, NIAID, NIH): CMVR 
VRC01 H, CMVR VRC01 L, from Dr. John Mascola
136,202; PVO, clone 4 (SVPB11) 
from Dr. David Montefeori and Dr. Feng Gao
203; ZM109F.PB4 SVPC13 from Dr. C. A. 
Derdeyn and Dr. E. Hunter
219, pNL4-3.Luc.R-.E- from Dr. Nathaniel Landeau
200,201, 
TZM-bl cells from Dr. John C. Kappes, Dr. Xiaoyun Wu, and Tranzyme Inc
195-199.  The 
variable heavy and light chains of b12 and PG16 were cloned into the CMVR VRC01 H 
and L plasmids.  SHIV-SF162P3N clone 8 and SHIV-SF162P3N clone 11 Env 60 
 
expression plasmids was a generous gift from Cecilia Cheng-Mayer.  Plasmids encoding 
TPST-2 and the envelope glycoproteins pNL4-3∆env, 89.6, ADA, SG3, SA32, YU2, 
JRFL, KB9, VSV-G, HIV-2 ST, SIVmac239, SIVmac316, and replicative 89.6 and SG3 
viruses were previously described
28,88,158,165,220.  Human embryonic kidney HEK293T 
cells were obtained from ATCC.  Cf2Th-CD4+.CCR5+ and CfTh-CCR5+ cells were a 
generous gift from Dr. Hyeryun Choe. 
Purification of CD4–Ig, eCD4-Ig variants, and antibodies.  Production of CD4-Ig, 
eCD4-Ig variants and antibodies was performed as previously described
169.  Briefly, 
HEK293T cells in 140 mm plates were transfected with 25 ug/plate at 50% confluency by 
the calcium phosphate transfection method.  Plasmids encoding sulfated proteins were 
cotransfected with a plasmid encoding human tyrosine protein sulfotranserase 2 (TPST2).  
At 12 hrs post-transfection, 10% FBS-DMEM media was replaced with serum-free 293 
Freestyle media (Invitrogen). Media was collected after 48 hrs, debris was cleared by 
centrifugation for 10 min at 1,500 g and filtered using 0.45 μm filter flasks (Millipore). 
Complete protease inhibitor cocktail (Roche) was added to the filtered supernatants.  500 
μl bed volume of Protein A sepharose beads (GE Healthcare) were added and were 
agitated 4°C overnight.  The bead/media mixture was collected by gravity flow column 
(Biorad) and was washed with 30 mL PBS (Lonza) + 0.5M NaCl (0.65M NaCl final) 
followed by 10 mL PBS.  Protein was eluted with 3M MgCl2 in phosphate buffered saline 
(PBS).  Buffer was exchanged for PBS and protein was concentrated to 1 mg/ml by 
Ultrafiltration (Amicon Ultra) at 4,000 g. 
Flow Cytometry Analysis of Envelope Glycoprotein Binding.  HEK293T cells were 
transfected with plasmids expressing envelope glycoprotein lacking cytopasmic residues 61 
 
732 to 876 (HXBc2 numbering) together with plasmid encoding the tat protein.  
Transfection medium was replaced after an overnight incubation and cells were harvested 
48 hours post transfection.  Harvested cells were washed twice in flow cytometry buffer 
(PBS with 2% goat serum, 0.01% sodium azide).  Cells were incubated with CD4-Ig or 
eCD4-Ig on ice for 1 hour and then washed twice with flow cytometry buffer.  A 
secondary antibody recognizing human Fc (Jackson Immuno Research) was added to the 
cells for 30 minutes.  Cells were washed twice with flow cytometry buffer, twice with 
PBS, and resuspended in 1% paraformaldehyde solution.  Binding was analyzed with an 
Accuri C6 Flow Cytometer (BD Biosciences) and data analyzed with the C6 Software 
(BD Biosciences). 
Viral enhancement assay.  HIV-1 pseudovirus expressing firefly luciferase was pre-
incubated with titrated amounts of CD4-Ig or eCD4-Ig variants in DMEM (10% FBS) for 
1 hour at 37°C.  CD4-negative Cf2Th-CCR5 cells were harvested and diluted in DMEM 
(10% FBS) to 100,000 cells/mL and added to the pseudovirus/inhibitor mixture.  Cells 
were then incubated for 48 hours at 37°C.  Viral entry was analyzed using Britelite Plus 
(Perkin Elmer) and luciferase was read using a Victor X3 plate reader (Perkin Elmer). 
HIV-1 Neutralization Assays.  GHOST-CCR5 or –CXCR4 cells were plated into 12-
well plates at 50,000 cells per well.  HIV-1 pseudovirus was diluted in RPMI and titrated 
amounts of CD4-Ig, fusion1, fusion2, or eCD4-Ig were added.  Virus and inhibitor were 
incubated at room temperature for 20 minutes and added to the cells for 2 hours at 37°C.  
Cells were then washed with serum free medium and then incubated in 1 mL of DMEM 
(10% FBS) for 48 hours at 37°C.  Cells were then trypsinized and resuspended in PBS 62 
 
(2% FBS), pelleted, and resuspended in a fixative solution (1% paraformaldehyde in 
PBS).  Viral entry was determined by flow cytometry based on GFP expression. 
For studies of infectious virus, unstimulated PBMCs were harvested and 
resuspended in RPMI medium (15% FBS, 20 U/mL IL-2).  Cells were plated in plated in 
a 12-well plate at 10
6 cells per well.  HIV-1 virus was diluted in RPMI and varying 
amounts of inhibitor were added.  The virus and inhibitor was incubated at room 
temperature for 20 minutes and added to the cells for 3 hours at 37°C.  Cells were then 
washed with serum-free medium and resuspended in fresh RPMI medium (15% FBS, 20 
U/mL IL-2).  At 3-day intervals post infection, supernatants were collected and fresh 
RPMI medium (15% FBS, 20 U/mL IL-2) was added to the cells.  Supernatants were 
analyzed for viral infection by ELISA with Alliance HIV-1 p24 antigen ELISA kit 
(Perkin Elmer). 
TZM-bl neutralization assays were performed as previously described
203.  Briefly, 
HIV-1 pseudoviruses were pre-incubated with titrated amounts of CD4-Ig or eCD4-Ig 
variants in DMEM (10% FBS) for 1 hour at 37°C.  TZM-bl cells were harvested and 
diluted in DMEM (10% FBS) to 100,000 cells/mL and added to the pseudovirus/inhibitor 
mixture.  Cells were then incubated for 48 hours at 37°C.  Viral entry was analyzed using 
Britelite Plus (Perkin Elmer) and luciferase was read using a Victor X3 plate reader 
(Perkin Elmer). 
Antibody-dependent cell-mediated cytotoxicity assays.  ADCC activity was performed 
as previously described
221.  Briefly, CEM.NKR CCR5 CD4+ T cells were infected for 4 
days with infectious HIV-1 NL4.3, SHIV-KB9, or SIVmac239.  After 4 days, KHYG-1 
effector cells were co-incubated with infected cells in the presence of titrated CD4-Ig, 63 
 
eCD4-Ig variants, or the b12 antibody for 8 hours.  ADCC activity was measured by 
luciferase activity as above. 
Production of HIV-1NL4-3 stocks.  A molecular clone of HIV-1NL4-3 were obtained from 
the AIDS Research and Reference Reagent Program (ARRRP), Division of AIDS, 
NIAID, NIH from material deposited by Suzanne Gartner, Mikulas Popovic, Robert 
Gallo and Malcolm Martin.  Virus stocks were produced in 293T cells by transient 
transfection using TurboFect (Thermo Scientific) and 12 µg of proviral plasmid.  
Supernatants were harvested at 40 hours, filtered through 0.45 µm filters, and dispensed 
into single use doses and frozen at -80°C.  Viruses were quantified by p24 ELISA 
(Zeptometrix, Buffalo, NY) and by GHOST cell titer
222 to determine infectious units per 
mL (IU/mL).  Titering was performed per the GHOST cell line protocol obtained through 
ARRRP. 
Hematopoietic stem cell isolation and NSG mouse transplantation.  Human CD34+ 
hematopoietic stem cells (HSC) were isolated from fetal livers obtained from Advanced 
Bioscience Resources, INC (ABR, Alameda, CA).  Tissue was disrupted and incubated 
with 1mg/mL Collagenase/Dispase (Roche Applied Sciences) for 15 min at 37⁰C.  Cells 
were isolated by passing the disrupted tissue through a 70 µm filter.  Red blood cells 
were lysed in BD Pharm Lyse (BD Biosciences, San Jose, CA), with CD34+ cells being 
isolated using CD34 MACS microbeads (Miltenyi) according to manufacturer’s 
instructions with an additional purification step using a second column.  NOD.Cg-Prkdc 
scid Il2rγ tm1Wj/Szj (NOD/SCID/IL2rγ
null, NSG) mice were obtained from Jackson 
Laboratories (Bar Harbor, ME).  Neonatal mice received 150 cGy radiation, and 2-4 
hours later 1x10
6 CD34+ HSCs in 1% heparin (Celgene, Summit, NJ) via intrahepatic 64 
 
injection.  Mice were monitored for engraftment levels of human CD45+ cells and 
development of T cells and B cells at 8, 10, and 12 weeks post engraftment. 
Mouse infections, treatment, and analysis.  Humanized mice with evidence of human 
CD4+ T cell development in blood were infected with 5x10
4 IU of HIV-1NL4.3 by 
intraperitoneal injection. Mice were administered with 65 μg of eCD4-Ig once weekly for 
the first 2 weeks, starting at 8 day prior to the HIV-1 challenge, and then twice weekly 
starting week 3 by retro-orbital injection while under anesthetization by 2.5% 
isofluorane.  Mock treated mice received a retro-orbital injection of PBS one and eight 
days preceding HIV-1 challenge, and were anesthetized in parallel with eCD4-Ig mice 
throughout.  Every week post-infection the mice were anesthetized by inhalation of 2.5% 
isoflourane and blood was collected retro-orbitally for analysis.  At week 6, three eCD4-
Ig treated mice and one mock treated mouse (who had not become infected) were 
challenged a second time with 5x10
4 IU HIV-1NL4-3.  Mouse blood was blocked for 20 
minutes at room temperature in FBS (Denville) and stained with appropriate antibodies 
for 15 minutes at room temperature.  Red blood cells were removed by incubation in BD 
FACS Fix/Lysing Solution (BD Biosciences), which was removed by dilution with PBS 
prior to analysis by flow cytometry.  HIV-1 levels in peripheral blood were determined 
by extracting viral RNA from mouse plasma at each blood draw using a viral RNA 
isolation kit (Qiagen, Germantown, MD) followed by Taqman One-Step RT-PCR (Life 
Technologies, Carlsbad, CA) using a primer and probe set targeting the HIV-1 LTR 
region, as previously described
223,224.  Reactions were performed and analyzed using a 
7500 Fast Realtime PCR System (Life Technologies). 65 
 
Flow cytometry.  Stained cells were acquired on a FACS Canto II (BD Biosciences) and 
analyzed using FlowJo software v7.6.5 (Tree Star Inc., Ashland, OR).  Blood samples 
were stained using human-specific antibodies at a 1:20 dilution for CD4-V450 (RPA-T4), 
CD8-APC (RPAT8), CD3-PE (UCHT1), and CD45-PerCP (TUI16) (BD Bioscience).  
Up to 10,000 events were recorded for viable cell populations and gated based on 
fluorescence minus one control as previously described
224. 
eCD4-Ig antibody concentrations in NSG mice.  In vivo concentrations of eCD4-Ig 
antibodies were measured by ELISA as previously described
129.  Briefly, to measure 
NSG mouse and macaque serum concentrations, ELISA plates (Costar) were coated with 
5 µg/mL HIV gp120 overnight at 4°C.  Plates were washed with PBS-T (PBS + 0.05% 
Tween-20) twice and blocked with 5% milk in PBS for 1 hour at 37°C.  Titrations of sera 
blocked with 5% milk in PBS were added to the plate and incubated for 1 hour at 37°C.  
Samples were washed five times with PBS-T and a horseradish peroxidase secondary 
antibody (Jackson Immuno Research) recognizing human IgG1.  Plates were incubated 
for 1 hour at 37°C and then washed ten times with PBS-T.  TMB solution (Fisher) was 
added for 10 minutes at room temperature and then stopped with TMB Stop Solution 
(Southern Biotech).  Absorbance was read at 450 nm by a Victor X3 plate reader (Perkin 
Elmer), and compared with a standard curve generated using a eCD4-Ig mixed with pre-
inoculation sera. 
AAV inoculation of rhesus macaques.  Three two-year old AAV1-negative male 
Indian-origin rhesus macaques were housed at the New England Primate Research Center 
in accordance with standards set forth by the American Association for Accreditation of 
Laboratory Animal Care.  These macaques were inoculated with 1 ml saline containing 2 66 
 
× 10
13 AAV1 particles delivering a self-complementary rh-eCD4-Ig
mim2 transgene (IgG2 
isotype) into both quadriceps (0.5 ml per quadriceps).  1 ml of sera was obtained at -4, -2, 
0, 2, 4, 6, 8, and 10 weeks post-inoculation. 
eCD4-Ig, rh-eCD4-Ig
mim2 and anti-rh-eCD4-Ig
mim2 antibody concentrations in NSG 
mice and rhesus macaque sera.   
In vivo concentrations of eCD4-Ig, rh-eCD4-Ig
mim2 and anti-rh-eCD4-Ig
mim2 antibodies 
were measured by ELISA as previously described
129.  Briefly, to measure NSG mouse 
and macaque serum concentrations, ELISA plates (Costar) were coated with 5µg/mL SIV 
gp120 overnight at 4°C.  Plates were washed with PBS-T (PBS + 0.05% Tween-20) 
twice and blocked with 5% milk in PBS for 1 hour at 37°C.  Titrations of sera blocked 
with 5% milk in PBS were added to the plate and incubated for 1 hour at 37°C.  Samples 
were washed five times with PBS-T and a horseradish peroxidase secondary antibody 
(Jackson Immuno Research) recognizing human IgG1 or rhesus CD4 was added.  Plates 
were incubated for 1 hour at 37°C and then washed ten times with PBS-T.  TMB solution 
(Fisher) was added for 10 minutes at room temperature and then stopped with TMB Stop 
Solution (Southern Biotech).  Absorbance was read at 450 nm by a Victor X3 plate reader 
(Perkin Elmer), and compared with a standard curve generated using a rh-eCD4-Ig
mim2 
mixed with pre-inoculation sera.   Anti-rh-eCD4-Ig
mim2 antibodies were measured in the 
same way except that ELISA plates were coated with rh-eCD4-Ig
mim2 and anti- rh-eCD4-
Ig
mim2 antibodies were measured using an anti-rhesus light-chain antibody, and compared 
with a standard curve generated using an anti-rhesus CD4 antibody. 
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3.D.  Results 
A C-terminal sulfopeptide markedly enhances the neutralizing activity of CD4-Ig.  
We reasoned that, due to the cooperativity between CD4-Ig and CCR5mim1
109,166, a 
fusion of the two would bind the envelope glycoprotein with higher affinity and avidity 
than either molecule alone.  We further hypothesized that inclusion of the CCR5mim1 
sulfopeptide would prevent association of CD4-Ig-bound virions with CCR5 or CXCR4, 
thereby limiting the ability of CD4-Ig to promote infection.  Finally, we anticipated that 
this fusion would retain or improve the ability of CD4-Ig to irreversibly inactivate virion-
associated Env
213.  To test these possibilities, three fusion proteins were initially 
generated (Figure 3.1A).  In fusion1, CCR5mim1 was fused to the amino-terminus of 
CD4-Ig.  In fusion2, the sulfopeptide was inserted at the junction between domain 2 of 
CD4 and the hinge region of the CD4-Ig Fc domain.  In fusion3, the sulfopeptide was 
fused to the C-terminus of the Fc domain.  Fusion3 was subsequently renamed eCD4-Ig 
for its enhanced potency.  In each case, a tetraglycine linker connects the sulfopeptide to 
CD4-Ig.  Each of these CD4-Ig variants neutralized R5, R5X4, and X4 isolates more 
efficiently than CD4-Ig (Figure 3.1B and not shown).  eCD4-Ig consistently 
outperformed fusion1 and fusion2, and neutralized an initial panel of clade B isolates and 
SIVmac316 with IC50s 10- to 100-fold lower than CD4-Ig (Figure 3.1C and not shown).  
Consistent with its potency, eCD4-Ig, but not CD4-Ig, halted replication of 89.6 and SG3 
viruses in PBMC at low nanomolar concentrations: 125 ng/mL (1.25 nM) and 500 ng/mL 
(5 nM), respectively (Figure 3.1D). 68 
 
 
Figure 3.1. Characterization of CD4-Ig/CCR5-mimetic peptide fusion proteins.  (A) CD4-Ig and 
fusion constructs with CCR5mim1 peptide are represented.  CD4-Ig is comprised of CD4 domains 1 and 2 
(blue) fused to a human IgG1 Fc domain (grey).  In fusion1, the CCR5mim1 sulfopeptide (red) is fused to 
the amino-terminus of CD4-Ig with a tetraglycine linker.  In fusion2, the tetraglycine linker and 
CCR5mim1 are inserted between the carboxy-terminus of CD4 domain 2 and the IgG1 hinge region.  In 
fusion3 (subsequently renamed eCD4-Ig), the sulfopeptide is fused to the carboxy-terminus of CD4-Ig, 
again preceded by a tetraglycine linker.  Figure also shows the sequence of CCR5mim1 aligned with that of 
the CCR5 amino-terminus.  Common residues, including four CCR5 sulfotyrosines, are shown in red.  An 
alanine in CCR5mim1 (blue) is substituted with a tyrosine in CCR5mim2, described below.  (B) HIV-1 
pseudotyped with the envelope glycoproteins of the 89.6 or ADA isolates was incubated with GHOST-
CCR5 cells and the indicated concentrations of CD4-Ig variants.  Infection was measured by flow 
cytometry 2 days later.  (C) Experiments similar to those in panel B using HIV-1 pseudotyped with the 
envelope glycoproteins of the JR-FL, YU2, KB9, or SIVmac316 isolates.  (D) Infectious 89.6 or SG3 HIV-
1 was incubated with PBMC in the presence of the indicated concentrations of CD4-Ig or eCD4-Ig.  
Supernatants were collected on the day indicated and viral p24 levels were measured by ELISA. 
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eCD4-Ig utilizes both sulfopeptides to avidly bind Env trimers. To better understand 
the markedly greater potency of eCD4-Ig relative to CD4-Ig, we compared the ability of 
each to bind cell-surface expressed HIV-1 envelope glycoprotein trimers (Figure 3.2A).  
eCD4-Ig bound these trimers more efficiently than did CD4-Ig, with half-maximum 
binding at 0.35 µg/ml, compared with 1.0 µg/ml for CD4-Ig.  eCD4-Ig saturated trimer-
expressing cells with approximately one-third less bound protein than CD4-Ig, indicating 
that eCD4-Ig associates with greater avidity than CD4-Ig, and that one-third of the CD4-
binding sites were occluded due to the presence of the sulfopeptide.  Although eCD4-Ig 
binds the envelope glycoprotein with higher avidity than CD4-Ig, comparison of Figures 
3.1B and 3.2A suggests that improved avidity does not fully account for the greater 
potency of eCD4-Ig in neutralization assays.  Consistent with this, eCD4-Ig was much 
less prone to promote HIV-1 infection in CCR5-positive, CD4-negative cells than was 
CD4-Ig (Figure 3.2B).  Thus the marked increase in potency of eCD4-Ig relative to CD4-
Ig can be explained, at least in part, by the higher avidity with which it binds HIV-
1envelope glycoprotein trimers and by its decreased ability to promote infection.  It is 
also possible that eCD4-Ig is more efficient than CD4-Ig at irreversibly inactivating Env.  
To explore the contribution of each sulfopeptide to the improved neutralization of eCD4-
Ig, we made a “knobs and holes” heterodimer of CD4-Ig and eCD4-Ig.  Relatively pure 
heterodimers could be generated (Figure 3.2C).  These CD4-Ig/eCD4-Ig consistently 
neutralized more efficiently than CD4-Ig, but less efficiently than eCD4-Ig (Figures 
3.2D-F).  Thus, consistent with our studies of sulfopeptide Fc fusions 
109, eCD4-Ig 
utilizes both of its sulfopeptides to neutralize HIV-1. 70 
 
 
Figure 3.2. Mechanistic studies of eCD4-Ig.  (A) 293T transfected to express 89.6 or ADA envelope 
glycoprotein were incubated on ice with indicated concentrations of CD4-Ig, eCD4-Ig, or IgG.  Binding 
was analyzed by flow cytometry using a secondary antibody recognizing the IgG1 Fc domain of these 
proteins.  (B) HIV-1 expressing luciferase and pseudotyped with enveloped glycoproteins of the ADA, JR-
FL, or 89.6 isolates or with VSV-G was incubated with Cf2Th-CCR5 cells in the presence of the titrated 
concentrations of CD4-Ig or eCD4-Ig.  Luciferase activity was measured two days post infection to assess 
viral infection, and normalized to the maximum value observed for each pseudovirus.  Experiments in 
panels A and B are representative of at least four with similar results.  (C) CD4-Ig, eCD4-Ig, and a CD4-
Ig/eCD4-Ig heterodimers were analyzed by SDS-PAGE and stained with Coomassie blue.  (D-F) HIV-1 
pseudotyped with the indicated envelope glycoprotein was incubated in triplicate with TZM-bl cells and 
varying concentration of CD4-Ig, eCD4-Ig, or a CD4-Ig/eCD4-Ig heterodimer shown in panel C. 
Luciferase activity was determined two days post-infection.   
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eCD4-Ig can bind three Env receptor binding sites without steric interference. 
We have previously observed enhancement of neutralization when CCR5mim1-Ig was 
mixed with CD4-Ig, but this effect was modest, implying that the CD4 domain of eCD4-
Ig and at least one sulfopeptide binds in cis, that is, from the same eCD4-Ig molecule.  
Figures 3.2C-F show that a heterodimer of eCD4-Ig and CD4-Ig neutralizes less 
efficiently than eCD4-Ig itself, indicating that both eCD4-Ig sulfopeptides contribute to 
neutralization.  To determine whether eCD4-Ig could access two CCR5-binding sites on 
Env while occupying one CD4-binding site, we built a model based on the cryo-electron 
structure of CD4-bound Env (Figure 3.3A-C), and fitted into this density the crystal 
structure of gp120 (blue) complexed to CD4 (red) and the tyrosine-sulfated antibody 
412d (sulfotryosines in green)
22,24,92,103.  The 412d heavy-chain sulfotyrosine 100 
occupies the same pocket bound by one CCR5 sulfotyrosine, presumed to be CCR5 
tyrosine 10
92.  We then positioned the structure of an Fc domain close to sulfotyrosine 
100 residues bound to two gp120 monomers and to the C-terminus of CD4 domain 2, 
while avoiding steric interference with the electron density defining CD4-bound Env 
(Figure 3.3D).  We observed that the Fc domain could be positioned so that residues 
absent from the crystal structures could readily bridge the distance from the Fc domain to 
CD4 domain 2, as well as the distances to each of the 412d sulfotyrosines (Figure 3.3E).  
Thus eCD4-Ig can simultaneously bind all three receptor-binding sites without steric 
interference.  Combining data from Figure 2 and our previous studies, we infer that 
eCD4-Ig binds Env with a unique three point, claw-like grip. 72 
 
 
Figure 3.3.  A model of eCD4-Ig bound to the HIV-1 envelope glycoprotein trimer.  (A) On the left, the 
structure (2QAD) of  gp120 (YU2 isolate) bound to the tyrosine-sulfated CD4i antibody 412d and CD4 
domains 1 and 2
92, was fitted into a cryoelectron micrograph of HIV-1 envelope glycoprotein (Bal isolate) 
bound to CD4
22.  gp120 and CD4 are shown in blue and red, respectively. 412d sulfotyrosines are 
represented as green (carbon), red (oxygen), and yellow (sulfur) spheres.  On the right, the Fc domain of 
human IgG1 (1FCC, cyan)
225 is oriented to avoid steric interaction with the envelope glycoprotein while 
minimizing distances between the carboxy terminus of domain 2 of CD4 and the amino-terminus of one Fc 
domain monomer, and between the carboxy-termini of the two Fc domain monomers and sulfotyrosine 100 
of the 412d heavy chain (Tys 100).  This sulfotyrosine occupies a pocket in gp120 thought to bind CCR5 
sulfotyrosine 10
159.  This pocket is also critical for binding CCR5mim1 and CCR5mim2
165,166.  Consistent 
with previous studies
109, the resulting distances are short enough to permit each sulfopeptide to bind a 
gp120 monomer (see panels d and e), whereas only one CD4 can bind .  For clarity only the bound CD4 is 
shown.  (B) The same structures shown in panel a, rotated 30 degrees about the horizontal axis. (C) The 
same structures shown in panel a rotated 90 degrees about the horizontal axis. (D) The same structure 
shown in panel a is rotated 30 degrees about the trimer axis to highlight distances between the carboxy-
terminus of CD4 and the amino-terminus of one Fc domain monomer (44.1 angstroms), between  the 
carboxy-terminus of the Fc domain monomer fused to the bound CD4 and Tys 100 bound in cis to the same 
gp120 monomer (33.4 angstroms), and the carboxy-terminus of the Fc domain monomer fused to the 
unbound CD4 and Tys 100 bound in trans to an adjacent gp120 monomer (37.2 angstroms, unbound CD4 
not shown).  (E) Residues not shown in the crystal structures that must span these distances are represented, 
bounded by residues visible in the crystal structures (boxed in gray).  Note that the distances spanned are 
well under the extension of a typical beta strand. 
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eCD4-Ig and its variants potently neutralized a diverse panel of tier 2 and tier 3 
isolates.  We further explored the breadth and potency of eCD4-Ig using a panel of 
neutralization resistant tier 2 and 3 viruses
95 from multiple HIV-1 clades, as well as 
SIVmac251 (Figure 3.4A and 3.5A).  In parallel, we assayed three additional eCD4-Ig 
variants.  In the first, eCD4-Ig
mim2, CCR5mim1 was replaced by CCR5mim2.  
CCR5mim2 differs from CCR5mim1 by single alanine 4 to tyrosine substitution (Figure 
3.1A), which increased its affinity for a number of HIV-1 envelope glycoproteins
166.  We 
also introduced a previously characterized glutamine 40 to alanine mutation into CD4 
domain 1 of eCD4-Ig (eCD4-Ig
Q40A)
214.  This modification has been shown to increase 
the affinity of CD4 for the gp120 molecules of some isolates.  Both mutations were 
combined into a final variant (eCD4-Ig
Q40A,mim2).  Each of these eCD4-Ig variants, 
including eCD4-Ig itself, substantially outperformed CD4-Ig for all viruses in the panel, 
typically improving neutralization potency of tier 2 and 3 isolates by 20 to >200-fold 
(Figure 3.4A and 3.5A).  Moreover, in contrast to CD4-Ig and bNAbs, eCD4-Ig 
efficiently neutralized every isolate tested.  For example IC80 value of 3BNC117 for the 
clade B isolate AC10.0.29 is reported >50 µg/ml
152, whereas eCD4-Ig and eCD4-Ig
mim2 
neutralized this isolate with IC80s of 0.7 and 0.5 µg/ml, respectively (7 and 5 nM; Figure 
3.5A).  Similarly, the reported IC80 of NIH45-46 for the clade D isolate 3016.v5.c45 was 
again >50 µg/ml
152, whereas eCD4-Ig and eCD4-Ig
mim2 both neutralized this isolate with 
IC80s of 0.1 µg/ml (1 nM).  Underscoring its exceptional breadth, eCD4-Ig also 
neutralized SIVmac251 with an IC50 of 0.006 µg/ml (60 pM), 33 times more efficiently 
than CD4-Ig.  In general, the more neutralization resistant a virus, the better eCD4-Ig and 
its variants performed relative to CD4-Ig.  In most cases, replacement of CCR5mim1 74 
 
with CCR5mim2 modestly improved neutralization.  Similarly, the Q40A mutation in 
CD4 domain 1 further improved eCD4-Ig and eCD4-Ig
mim2 neutralization of most HIV-1 
isolates, but not of SIVmac251.  The IC50 and IC80 values shown in Figure 3.4 and Figure 
3.5 compare favorably with those of previous studies of bNAbs using the same isolates 
(compare the final columns of Figure 3.4A).   
We then evaluated eCD4-Ig, eCD4-Ig
mim2, eCD4-Ig
Q40A,mim2 and the bNAb 
NIH45-46 with a panel that included nearly every isolate previously shown to be resistant 
to either or both of the two best CD4bs antibodies, NIH45-46 or 3BNC117 (Figure 3.4B 
and 3.5B).  Again both eCD4-Ig variants efficiently neutralized every isolate assayed and 
substantially more efficiently that CD4-Ig, with IC50s ranging from <0.001 µg/ml to 
1.453 µg/ml.  In contrast, 26 isolates were resistant to NIH45-46, and 29 isolates have 
been previously reported resistant to 3BCN117.  Thus, eCD4-Ig variants but not CD4-Ig 
efficiently neutralized tier 2 and 3 isolates with potencies comparable to those reported 
for highly potent bNAbs, as well as all of 38 isolates resistant to one or both of the best 
CD4-binding site bNAbs. 75 
 
 
Figure 3.4.  eCD4-Ig variants efficiently neutralize Tier 2 and Tier 3 HIV-1 and SIV isolates. 
(A) The IC50 values (µg/mL) of CD4-Ig, eCD4-Ig, eCD4-Ig
mim2, eCD4-Ig
Q40A, and eCD4-Ig
Q40A,mim2 against 
24 viral isolates selected for their neutralization resistance are shown.  HIV-1 pseudotyped with the 
indicted envelope glycoprotein was incubated in triplicate with TZM-bl cells and varying concentrations of 
CD4-Ig or the indicated eCD4-Ig variant.  Luciferase activity was determined two days post-infection. 
‘Fold’ indicates the ratio of the IC50 value of CD4-Ig to the IC50 value of the geometric mean of the assayed 
eCD4-Ig variants. The geometric mean of CD4bs antibodies 3BCN117, NIH45-46, and VRC01 was 
calculated from values reported in Huang et al. and Sheid et al.
137,152  (B) Experiments similar to those in 
panel a except that the IC50 values of CD4-Ig, eCD4-Ig
mim2, eCD4-Ig
Q40A,mim2 and NIH45-46 were 
determined for a panel of 40 viral isolates selected for resistance to the CD4bs bNAbs 3BNC117 and 
NIH45-46.  IC50 values of the CD4bs antibodies VRC01, NIH45-46, and 3BNC117 listed in the three 
rightmost columns were reported in Huang et al. and Scheid et al.
137,152  76 
 
 
 
Figure 3.5.  IC80 values of for eCD4-Ig variants assayed in Figure 3.4.  (A) IC80 values (µg/mL) of CD4-
Ig, eCD4-Ig, eCD4-Ig
mim2, eCD4-Ig
Q40A, and eCD4-Ig
Q40A,mim2 against 24 viral isolates selected for their 
neutralization resistance are shown, determined as described in Figure 3.4 legend.  Right panel includes 
published IC80 values
152 for the CD4bs antibodies VRC-01, NIH45-46, and 3BNC117, and the geometric 
mean of the IC80 values of eCD4-Ig variants and these CD4bs antibodies.  (B) IC80 values (µg/mL) of CD4-
Ig, eCD4-Ig
mim2,  and eCD4-Ig
Q40A,mim2, and NIH45-46 against 40 viral isolates, 38 of which are resistant to 
either NIH45-46 or 3BNC117.  Right panel includes published IC80 values
152 for the CD4bs antibodies 
VRC-01, NIH45-46, and 3BNC117.  ‘Fold’ indicates the ratio of the IC80 value of CD4-Ig to the IC80 value 
of the geometric mean of the assayed eCD4-Ig variants. 77 
 
 
We then directly compared ability of CD4-Ig, the eCD4-Ig variants eCD4-Ig
mim2, 
eCD4-Ig
Q40A,  and the bNAbs VRC01, NIH45-46, and IgGb12 to neutralize the 
neutralization resistant SIV isolate SIVmac239 as well as HIV-2 ST and several 
additional clade B and C HIV-1 isolates (Figure 3.6A and Figure 3.7A)
226. Again, eCD4-
Ig and its variants neutralized all six HIV-1 isolates with efficiencies comparable to or 
better than these bNAbs.  Moreover, eCD4-Ig and its variants, but not any of these 
bNAbs, efficiently neutralized HIV-2 ST and SIVmac239.  As was observed with 
SIVmac251, the variant bearing the Q40A mutation was less efficient at neutralizing 
SIVmac239 and HIV-2 ST than those without this mutation.   78 
 
 
Figure 3.6. Comparison of eCD4-Ig variants and HIV-1 neutralizing antibodies.  
(A) HIV-1 pseudotyped with the envelope glycoproteins of the indicated HIV-1, HIV-2 or SIV isolates 
were incubated in triplicate with TZM-bl cells and the indicated concentrations of CD4-Ig, eCD4-Ig 
variants, or the CD4bs antibodies IgGb12, VRC-01 or NIH45-46.  Error bars represent standard errors. (B) 
Experiments similar to those in panel a except that a wider array of entry inhibitors (continued on p. 79)   79 
 
(continued) was characterized with HIV-1 pseudotyped with the SG3, YU2, or JR-CSF isolates, and IC50 
values are plotted.  eCD4-Ig variants are represented with blue, CD4-Ig and the tetrameric CD4-Ig 
construct PRO-542 with red, and HIV-1 neutralizing antibodies with green, grey, and white.  (C) Antibody-
dependent cell-mediated cytoxicity (ADCC) was measured using CEM.NKR-CCR5 target cells incubated 
with infectious HIV-1NL4-3, SHIVKB9 or SIVmac239 for four days.  Cells were then incubated with KHYG-1 
NK effector cells
227 for 8 hours in the presence of the indicated concentrations of CD4-Ig, eCD4-Ig 
variants, or the HIV-1 neutralizing antibody IgGb12, and ADCC activity was measured as loss of luciferase 
activity from the target cells.  Experiments are representative of two (panels A and C) or three (panel B) 
with similar results. 80 
 
 
Figure 3.7.  Extended neutralization assays, IC90 values, and standard errors for the studies of Figure 
3.6.   (A) TZM-bl neutralization studies of the indicated isolates as described in Figure 3.6A.  (B) IC90 
values for the experiments shown in Figure 3.6B, presented in the same format.  (continued on p.81)       81 
 
(continued) (C) Numeric IC50 and IC90 values of the experiment shown in Figure 3.6B, using the same color 
coding of Figure 3.4 and Figure 3.5.  Standard errors are also indicated below their IC50 and IC90 values. 
 
We further compared eCD4-Ig, eCD4-Ig
mim2 and eCD4-Ig
Q40A,mim2 using three 
additional HIV-1 isolates and a broader set of antibodies and inhibitors (Figure 3.6B, 
3.7B and 3.7C).  eCD4-Ig and variants neutralized SG3 and YU2 more efficiently than 
any members of this broader panel.  However five antibodies – PG9, PG16, PGT128, 
PGT121, and PGT145 – neutralized JR-CSF more efficiently than any eCD4-Ig variant.  
Note, however, that four of the antibodies more potent against JR-CSF (grey in Figure 
3.6B) did not neutralize SG3 at the maximum concentration of 10 µg/ml.  All eCD4-Ig 
variants neutralized these isolates with IC50s less than 0.3 µg/ml (3 nM) and all 
neutralized more efficiently than CD4-Ig, the tetrameric CD4-Ig variant PRO-542
212, or 
the antibodies 2G12, 4E10, and VRC01.  The potency of eCD4-Ig and its variants was 
reflected in the strikingly greater efficiency with which they mediated antibody-
dependent cell-mediated cytotoxicity (ADCC).  eCD4-Ig, eCD4-Ig
mim2, and eCD4-
Ig
Q40A,mim2 each facilitated more efficient killing of infected cells by CD16+ natural killer 
cells
227 than did CD4-Ig or the antibody IgGb12 (Figure 3.6C).  All eCD4-Ig variants 
performed similarly, approximately 30-40 times more efficiently than CD4-Ig, except 
that the variant bearing the Q40A mutation was again less efficient against SIVmac239.  
Thus the carboxy-terminal modification of eCD4-Ig did not interfere with the ADCC 
effector function of its Fc domain. 
Figure 3.8 presents a comparison of the neutralization studies compiled from the 
experiments shown in Figures 3.4-3.7 and from previous studies.  It shows that, even 
excluding SIV, HIV-2, and antibody resistant HIV-1 viruses, the geometric means of the 82 
 
IC50 and IC80 values of eCD4-Ig and its variants is roughly 3-4 times lower than that of 
VRC01, NIH45-46, or 3BNC117, and is 20-50 times lower than that of CD4-Ig.  
Moreover, each eCD4-Ig variant neutralized 100% of the isolates assayed.  In fact we 
have yet to identify or select an HIV-1, HIV-2 or SIV isolate that could not be efficiently 
(IC50 < 1.5 µg/ml) neutralized by eCD4-Ig.  We conclude that eCD4-Ig is as least as 
potent as the best HIV-1 bNAbs and is broader than any bNAb. 83 
 
 
Figure 3.8. A summary of HIV-1, HIV-2 and SIV neutralization studies. 
The IC50 and IC80 values from studies of Figures 3.4, 3.5, 3.6 and 3.7 are summarized.  The numbers of 
isolates that were not 50% (A) or 80% (B) neutralized by 50 µg/ml of the indicated inhibitors are listed on 
top.  Dots indicate IC50 and IC80 values of the remaining neutralized isolates.  Geometric means are 
calculated for neutralized isolates only and are indicated with a horizontal line.  Note that these data include 
SIV and HIV-2 isolates as well as 38 HIV-1 isolates selected to be resistant to NIH45-46 or 3BNC117, so 
that isolates resistant to these antibodies are over-represented.  Data for VRC01 and 3BNC117 were 
reported in Huang et al. and Scheid et al.
137,152  Data for NIH45-46 includes data from these sources as well 
as from Figures 3.4 and 3.5. 84 
 
eCD4-Ig retains its efficacy in vivo.  To determine if eCD4-Ig
 retained its potency in 
vivo, we inoculated four humanized NOD/SCID/γc (NSG) mice with sufficient eCD4-
Ig
mim2 to maintain serum titers of 2-4 µg/ml (Figure 3.9A). These mice, as well as six 
humanized control NSG mice were then challenged intravenously with 5×10
4 p24 
infectious units of HIV-1NL4-3 (Figures 3.9B-D).  No virus could be detected in any of the 
four eCD4-Ig
mim2 inoculated mice, whereas 5 of 6 control animals were infected.  Five 
weeks later, we rechallenged three of the previously challenged eCD4-Ig
mim2-treated 
mice, and the single uninfected control mouse.  Again, no eCD4-Ig
mim2-treated mouse 
was infected, whereas the uninfected control mouse became infected.  Thus eCD4-Ig
mim2 
can protect a humanized mouse from a high-dose HIV-1 challenge. 
 
Fig 3.9. In vivo activity of eCD4-Ig in humanized mice. (A) eCD4-Ig stability in NSG mice measured 
over the course of 11 days.  65 µg of eCD4-Ig was administered to 8 NSG mice via retro orbital injection.  
Samples were taken at days 1, 4, 7, and 11 post injection and titers were analyzed by ELISA.  (B) Infection 
curves of eCD4-Ig treated (blue line, n = 4) or mock treated with PBS (red line, n = 6) (continued on p.85) 85 
 
(continued) humanized NSG mice challenged with HIV-1NL4-3.  Mice were monitored weekly over the 
course of nine weeks. Three uninfected eCD4-Ig treated mice and one uninfected mock treated mouse were 
challenged a second time with the same virus and titers, as indicated.  Values indicate percent of mice 
detectably infected.  (C) Viral loads in RNA copies/mL are shown for each humanized mouse of panel B.  
Mice treated with eCD4-Ig are indicated with blue lines and mice treated with PBS are indicated with red 
lines. The 800 copies/mL limit of detection of this assay is indicated by a dashed line.  (D) Average eCD4-
Ig titers for each mouse in both the eCD4-Ig- and mock-treated groups from the humanized NSG mouse 
challenge study in Figure 3.9B-C.  Samples were taken 1-3 days post eCD4-Ig each week.  Dashed line 
indicates the limit of detection of the assay at 1 ng/mL. 
 
The in vivo properties of eCD4-Ig variants were further investigated in rhesus 
macaques using a rhesus macaque form of eCD4-Ig
mim2 (rh-eCD4-Ig
mim2).  To minimize 
potential adverse reactions in vivo, the Fc domain of the rh-eCD4-Ig
mim2 was generated 
from rhesus macaque IgG2, which binds Fc receptors and complement components less 
efficiently than IgG1.  A gene expressing this rh-eCD4-Ig
mim2 was inserted into a self-
complementary AAV (scAAV) vector, and 2 × 10
13 AAV1 particles delivering this 
vector were administered into the quadriceps of three 2-year old, Indian-origin, male 
rhesus macaques.  To promote efficient sulfation of the CCR5mim2 component, a 
separate scAAV vector expressing rhesus tyrosine-protein sulfotransferase 2
228 (TPST-2) 
was also administered in the same injections at a 1:10 ratio with scAAV-rh-eCD4-Ig
mim2.  
Note that, although this TPST-2 vector improves eCD4-Ig sulfation in in vitro studies 
(not shown), it is not yet clear whether it does so in vivo.  Blood was collected from 
AAV-inoculated macaques at -4, -2, 0, 2, 4, 8 and 10 weeks after administration and sera 
were analyzed for rh-eCD4-Ig
mim2 concentrations and anti-rh-eCD4-Ig
mim2 antibody 
responses.  rh-eCD4-Ig
mim2 titers stabilized to 6-12 µg/ml by week 10 (Figure 3.10A), 
indicating the transgene expressed efficiently, but at somewhat lower levels than has been 
reported with antibody-like immunoadhesins delivered with a similar vector
129.  No 
adverse reactions were observed for any macaque throughout the experiment. 86 
 
 
Fig 3.10. Characterization of rh-eCD4-Ig
mim2 in rhesus macaques.  (A) Sera titers of rh-eCD4-Ig
mim2 
from animals 255-12, 258-12, and 260-12 at the indicated weeks post AAV inoculations were measured by 
ELISA with immobilized SIV gp120.  (B) Anti-transgene response measured by ELISA with immobilized 
rh-eCD4-Ig
mim2 using sera samples from the indicated weeks post scAAV inoculation.  Dotted line 
indicates limit of detection as determined by an anti-rhesus CD4 antibody.  All titers were below this limit 
equivalent to 0.0014 µg/ml of an anti-rhesus CD4 antibody.  (C) A standard curve used to determine limit 
of detection of the anti-rhesus CD4-Ig antibody in panel b.  Limit of detection is again represented with a 
dotted line.  (D) HIV-1 pseudotyped with 89.6 or SF162 envelope glycoproteins was pre-incubated with 
sera samples obtained 2 weeks before (‘pre’) or 10 weeks (‘wk 10’) after scAAV inoculation, or with pre-
inoculation sera spiked in vitro with purified rh-CD4-Ig or rh-eCD4-Ig
mim2 to a concentration of 10 µg/mL, 
based on the ELISA measurements of panel A. 
 
Studies in rhesus macaques using adeno-associated virus (AAV) vectors to 
express neutralizing antibodies or CD4-Ig have shown that anti-transgene antibody 
responses can emerge, and that these responses can interfere with the activity of AAV-
delivered inhibitors
129.  For example, the majority of 12 macaques expressing the anti-
SIV antibodies 5L7 or 4L6 produced antibodies recognizing these AAV-expressed 
antibodies detectable four to six weeks after administration of the AAV vector (S.F., 
R.C., in preparation).  Similarly, Johnson et al. reported that two of three macaques 
expressing a single-chain immunoadhesin form of 5L7 also generated anti-
immunoadhesin responses, although no such response was observed with the 4L6 87 
 
immunoadhesin
129.  The same study observed that one of three macaques expressing 
approximately 5 µg/ml of a rhesus form of CD4-Ig (N4-Ig) developed an anti-N4-Ig 
response in the same time frame.  In contrast, anti-rh-eCD4-Ig
mim2 antibody responses 
could not be detected through week 10 in any of the three macaques expressing this 
transgene (Figure 3.10B-C).  These data suggest that rh-eCD4-Ig
mim2 is not more 
immunogenic than N4-Ig, 5L7, or 4L6 in rhesus macaques. 
To determine if AAV-expressed rh-eCD4-Ig
mim2 retained its activity in vivo, we 
compared sera from the three inoculated macaques with pre-inoculation sera mixed with 
rh-CD4-Ig or rh-eCD4-Ig
mim2 at the same concentrations.  Serum from all three 
inoculated macaques neutralized two HIV-1 isolates with 40-50% of the activity of sera 
mixed with the same concentrations of rh-eCD4-Ig
mim2 indicating that they expressed 
approximately 3-5 µg/ml of functional rh-eCD4-Ig
mim2 (Figure 3.10D).  No neutralization 
was observed with rh-CD4-Ig mixed with pre-inoculation sera.  Note that the IC50s 
observed in Figure 4d are higher than those in Figs. 1 and 3, because the rhesus CD4 
ortholog binds the 89.6 and SF162 envelope glycoprotein much less efficiently than does 
human CD4 (ref. 
229 and Figure 3.11A).  Thus rh-eCD4-Ig
mim2 can be expressed 
efficiently as an AAV transgene, and it retains much but not all of its activity in vivo. 
Next, we sought to evaluate the potency of rhesus-eCD4-Ig
mim2 as this will be 
used in future non-human protection and therapy experiments.  We first observed that rh-
eCD4-Ig
mim2 was less potent as the human-eCD4-Ig (Figure 3.11A).  We tested this 
construct in neutralization assays on three isolates: SF162P3N Clone 11, SHIV-AD8, and 
SIVmac239.  In all three cases, rhesus-eCD4-Ig
mim2 performed less efficiently than 
human eCD4-Ig, including - surprisingly - on SIVmac239 (Figure 3.11B).  In an attempt 88 
 
to restore potency, we made three human CD4 residues into the rhesus CD4 portion of 
rhesus-eCD4-Ig
mim2: I39N, K59R, and C66N.  The I39N mutation increased 
neutralization of SHIV-AD8 and SHIV-SF162P3N Clone 11 but not SIVmac239 (Figure 
3.11B).  Because of the presumable “claw-like” binding mechanism by which eCD4-Ig 
binds Env, we speculated the IgG hinge could modulate neutralization.  Thus we deleted 
three residues preceding the hinge (SST) that predicted to be O-glycosylated, which 
might impact the hinge flexibility.  This deletion had no effect on neutralization on either 
SHIV-AD8 or SIVmac239 (Figure 3.11C).  Interstingly, changing from rhesus-IgG2 to 
rhesus-IgG1 had the greatest effect on SIVmac239 (Figure 3.11D).  Finally, we then 
swapped out domain 1 of rhesus-eCD4-Ig
mim2 with human CD4 domain 1.  The eCD4-Ig 
variant composed of human CD4 domain 1 with rhesus IgG2 and CCR5mim2 did not 
have an impact on potency as it neutralized at a similar level as the I39N rhesus variant 
(Figure 3.11D).  Through this effort, we determined that the I39N variant will be suitable 
for SHIV challenge and therapy experiments while the rhesus IgG1 variant will be used 
in future SIV challenge and therapy experiments. 
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Figure 3.11. Characterizing rh-eCD4-Ig
mim2 variants to gain sensitivity on SIV and SHIV isolates.  
(A) TZM-bl neutralization assay comparing human eCD4-Ig, human CD4-Ig, rhesus eCD4-Ig
mim2, and 
rhesus CD4-Ig.  (B) rh-eCD4-Ig
mim2 variants with either the I39N, K59R, or C66N mutations were testested 
against SIVmac239, SHIV-AD8, and SHIV-SF162P3N Clone 11 isolates by TZM-bl neutralization assay.  
(C) TZM-bl neutralization assay comparing rh-eCD4-Ig
mim2 variant with deletion of possible O-
glycosylated residues by by the hinge region (SST del) with eCD4-Ig on SIVmac239 and SHIV-AD8 
isolates.  (D) TZM-bl assay comparing rh-eCD4-IgG1
mim2 and a variant that swapped rhesus CD4 domain 
with human CD4 domain 1 (hu-D1-rh-D2-eCD4-IgG2
mim2) with eCD4-Ig on SIVmac239. 90 
 
Lastly, we wanted to test whether using single-stranded AAV (ssAAV) vectors 
could improve rh-eCD4-Igmim2 transgene expression in macaques.  The ssAAV vectors 
contain components shown to increase transgene expression such as a wood chuck 
element (WPRE) and a full CMV promoter.  For this study, we used the I39N variant 
described in Figure 3.11.  When using the ssAAV vectors containing a full CMV 
promoter and WPRE, we observed greater expression of rh-eCD4-Ig
 I39N,mim2 in macaques 
with titers peaking at greater than 100 µg/mL in three of the four macaques we tested 
(Figure 3.12A).  However, the greater expression did not come without consequence as 
we were able to detect antibodies against the rh-eCD4-Ig
 I39N,mim2 construct in all four 
animals (Figure 3.12B).  Expectedly, immunogenic response we detected correlates with 
the drop in rh-eCD4-Ig
I39N,mim2 titers seen after week 6.  However, in this study, we also 
increased the amount of TPST-2 AAV inoculation to 20%.  At this level, we observed the 
expressed rh-eCD4-Ig
I39N,mim2 retained 100% of its activity at weeks 4 and 6 post AAV 
inoculation (Figure 3.12C-D). 91 
 
 
Figure 3.12.  rh-eCD4-Ig
I39N,mim2 expression with ssAAV vectors.  Similar experiments as performed in 
Figure 3.10.  (A) Sera titers of rh-eCD4-Ig
I39N,mim2 from animals 180-10, 181-10, 265-10, and 431-10  the 
indicated weeks post ssAAV inoculations were measured by ELISA with immobilized SIV gp120.  (B) 
Anti-transgene response measured by ELISA with immobilized rh-eCD4-Ig
mim2 using sera samples from 
the indicated weeks post AAV inoculation.  (C) HIV-1 pseudotyped with 89.6 envelope glycoproteins was 
pre-incubated with sera samples obtained 2 weeks before (‘pre’), 4 weeks (‘Week 10’), or 6 weeks (‘Week 
6’)  after ssAAV inoculation, or with pre-inoculation sera spiked in vitro with purified rh-CD4-Ig or rh-
eCD4-Ig
I39N,mim2 to a concentration of 10 µg/mL, based on the ELISA measurements of panel A. 
 
3.D.  Discussion 
Taken together, our data show that eCD4-Ig and its derivatives are at least as 
potent as most well-characterized bNAbs and broader than any bNAb.  The reason for 
their unusual breadth is clear: eCD4-Ig binds solely the CD4- and coreceptor-binding 
sites of gp120.  These sites are functionally important and highly conserved
230,231, 
consistent with eCD4-Ig’s ability to potently neutralize 100% of the HIV-1 isolates 92 
 
assayed and its unique ability to efficiently neutralize SIV and HIV-2 isolates.  In 
contrast, the gp120 epitopes of bNAbs are larger than these sites, and in every case 
include variable residues that allow viruses to evade neutralization without loss of 
fitness
91,188. 
The reasons for eCD4-Ig’s potency, however, are more complicated.  It is clear 
that the CCR5-mimetic sulfopeptide in eCD4-Ig blunts the ability of CD4-Ig to promote 
infection.  It is also apparent that the sulfopeptide and CD4 components of eCD4-Ig can 
simultaneously engage one or more HIV-1 envelope glycoprotein, because eCD4-Ig
mim2 
is markedly more potent than mixtures of CCR5mim2-Ig and CD4-Ig
166.  Further, the 
CD4 domain of eCD4-Ig cooperatively enhances the affinity of its two sulfopeptides, 
which, in contrast to the CD4 domains, can each bind one monomer of the envelope 
glycoprotein trimer
109,165.  Thus, although CD4-Ig and most bNAbs can bind only one 
trimer epitope, eCD4-Ig has the potential to bind three with high affinity – one CD4-
binding site and two coreceptor-binding sites (Figure 3.3).  The ability of eCD4-Ig to 
generate more potent ADCC than CD4-Ig or an HIV-1 neutralizing antibody is also of 
interest, especially since, at higher concentrations, more CD4-Ig molecules bind cell-
expressed envelope glycoproteins than eCD4-Ig molecules (Figure 3.2A).  This 
observation may suggest that some Fc domains are more favorably oriented toward 
effector-cell CD16
227, or that natural killer cells more efficiently recognize a localized 
array of Fc domains.  
Highly potent anti-HIV-1 bNAbs have been a recent focus of intense interest for 
several reasons.  First, they provide insight into the properties of antibodies that an HIV-1 
vaccine should elicit, and perhaps provide guideposts in step-wise efforts to raise these 93 
 
antibodies
226.  The example of eCD4-Ig provides similar insight.  Its potency relative to 
CD4-Ig underscores one challenge to eliciting potent CD4bs bNAbs: to be broad, such an 
antibody must bind similarly to CD4, but to be potent, an antibody must suppress its 
ability to promote infection.  Indeed, the best CD4bs neutralizing antibodies are much 
less efficient than sCD4 at inducing the CCR5-binding epitope of CD4i antibodies
137 .  
The potency of eCD4-Ig also highlights the ability of CCR5mim1 and CD4i antibodies to 
improve access to the CD4-binding sites of the envelope glycoprotein trimer
22,109.  Thus 
broad CD4i antibodies might enhance the potency of the many CD4bs antibodies in sera 
that are less potent than for example 3BNC117 or NIH45-46.  
A second reason that bNAbs are of interest is their potential to prevent or treat an 
HIV-1 infection
188-190.  We have shown that eCD4-Ig when passively administered retains 
its activity in vivo, protecting humanized mice from a high-dose HIV-1 challenge.  
Although passive administration remains difficult and expensive, gene therapy 
technologies, including those using AAV vectors, make possible stable, long-term 
expression of bNAbs or inhibitors like eCD4-Ig
129,232-234. Antibody-like immunoadhesins 
and bNAbs delivered as AAV transgenes have been demonstrated to protect rhesus 
macaques and humanized mice, respectively, from SIV or HIV-1 challenges
129,232.  In this 
context, eCD4-Ig has several advantages over any bNAb or related CD4i antibody/CD4 
fusion construct
168,173.  It has fewer non-self antibody and T-cell epitopes than heavily 
hypermutated bNAbs, and unlike antibodies, it is small enough to be delivered through 
more efficient self-complementary AAV vectors
233.  The conservation of the eCD4-Ig 
binding sites on gp120 suggests that emergence of escape variants is less likely than with 
a bNab, and viruses that do bypass prophylaxis may be less replicative in the continued 94 
 
presence of eCD4-Ig, and thus less likely to be retransmitted.  If so, an AAV-delivered 
eCD4-Ig might also be useful as a supplement to or replacement for current antiretroviral 
regimens, especially when compliance with these regimens is a concern. 
A key hurdle to the use of AAV vectors is the possibility that the expressed 
transgene will be cleared or inactivated by an anti-transgene antibody response.  
However, in contrast to previous and concurrent primate studies of antibody-like 
immunoadhesins
129 or full-length antibodies expressed from AAV-delivered transgenes, 
none of three rhesus macaques treated with scAAV-rh-eCD4-Ig
mim2 raised an anti-
transgene antibody response.  The relatively low titers of eCD4-Ig in these animals (<15 
µg/mL) may account for the absence of an endogenous antibody response.  We did, 
however, observe an anti-transgene response when using the I39N variant in the ssAAV 
vectors.  The anti-transgene response in this case might have been caused from the I39N 
mutation or from higher titers (>100 µg/mL) of the transgene.  Higher-powered in vivo 
studies will be necessary in order to determine which eCD4-Ig variants are more 
immunogenic and what levels of transgene can be tolerated without yielding an anti-
transgene response.  Encouragingly, rh-eCD4-Ig
mim2 retained much, or all, of its efficacy 
in macaque sera, especially when raising the amount of TPST-2 to 20% of the 
innocualted AAV.  The observed levels of eCD4-Ig expression for both scAAV and 
ssAAV vectors, if sustained in humans, would likely prevent most HIV-1 transmission 
events.  These properties of eCD4-Ig and its variants, combined with their exceptional 
potency and unmatched breadth, suggest that this class of inhibitors can be useful as 
microbicides, as supplements to antiretroviral therapies, or as expressed transgenes in an 
alternative vaccine. 95 
 
 
 
 
 
 
 
 
 
CHAPTER 4: DISCUSSION 
 
Implications for the Development of an HIV-1 Vaccine   96 
 
 
  The current work has highlighted the advantages of targeting the CD4- and 
coreceptor-binding sites on Env.  Without a convential HIV-1 vaccine, we must look to 
alternative approaches for targeting the several vulnerable sites of Env.  In this chapter, 
we will discuss the state of HIV-1 vaccine efforts and the antibody responses observed in 
the current vaccine trials.  We then focus on antigen design and the important factors of 
HIV-1 antibody development.  The use of bNAb cocktail therapies and the possible role 
of CD4i antibodies in these cocktails is considered.  Finally, the prophylactic and 
therapeutic uses of AAV-delivered eCD4-Ig is examined. 
4.A. The state of HIV-1 vaccine efforts 
There have been numerous efforts to make an effective HIV-1 vaccine.  In the 
early 1990’s, rhesus macaques given a live attenuated virus (SIVmac239/nef-deletion) 
had 100-fold lower viral loads than macaques receiving the wild-type strain
235,236.  This 
nef-deletion attenuated virus elicited a high antibody response, although it was unknown 
whether the resulting antibodies were bNAbs.  Trials using an engineered nef-deleted 
attenuated virus were halted when a later report showed that this virus was infectious in 
infant macaques
237.  Since then, the vaccine field has moved to subunit antigens and non-
replicating viral vectors in place of an attenuated virus vaccine strategy.  However, it is 
worth noting that live attenuated vaccines can generate T-cell responses which control 
infection.  Indeed, accumulated data suggest that vaccines that use both arms of the 
immune response will be more effective compared to those focusing on cellular or 
humoral responses alone. 97 
 
One step in this direction was the RV144 Thai trial.  In this trial, the cohort was 
primed with an inert canarypox viral vector delivering recombinant forms of HIV-1 gag, 
pol, and env.  The vaccine recipients were then given a boost of a recombinant gp120 
from clades B and E.  In this trial, vaccine recipients were 31% less likely of becoming 
infected compared to the placebo group
238.  Since the report was published, the antibody 
response from this cohort has been analyzed extensively.  One of the studies found that 
IgG antibodies targeting the V1/V2 loop were detected in individuals who received the 
vaccine
239.  However, no neutralizing antibodies were detected in any individual.  Thus 
continuous stimulation of the humoral response and ongoing evolution of Env may be 
necessary to drive the numerous rounds of somatic hypermutation apparently necessary 
to generate bNAbs.  A recent vaccine study in rhesus macaques identified V1/V2 loop 
antibodies as a correlate of protection
240.  Some studies have suggested a role protection 
for the ADCC, which requires less potent antbodies such as those found in the RV144 
Thai trial participants.  However, it is still unclear if V1/V2 loop antibodies and ADCC-
mediating antibodies are sufficient for an HIV-1 vaccine, or whether they are a byproduct 
of the immediate immune response following Env exposure. 
Other vaccine studies attempt to induce a T-cell response that would be able to 
protect from a wide array of HIV-1 isolates.  To achieve an effective T-cell response, 
mosaic vaccines have been developed that combine elements from all known HIV-1 
isolates for various viral proteins including Gag, Pol, and Env
241,242.  Delivered after 
priming with an adenoviral vector, these vaccines are thought to boost specific immune 
responses that prevent infection against a broad range of HIV-1 isolates.  Challenge 
studies have shown that this vaccine strategy (Ad prime followed by mosaic vaccine 98 
 
boost) has some effectiveness against both SIVmac251 and SHIV-SF162P3 
infection
243,244.  Although anti-Env antibodies were observed, these antibodies could only 
efficiently neutralize tier 1 isolates, moderately neutralize some tier 2 isolates, but not tier 
3 isolates. 
  A recent vaccine failure was the HVTN 505 trial which uses a similar approach 
with DNA vectors carrying Gag, Pol, Nef, and Env followed by a recombinant Ad5 
boost
245.  Results demonstrated a CD8+ T-cell response against Env.  However, previous 
studies have pointed out that this kind of response does not yield protection.  An initial 
animal study showed that no bNAbs were produced by this vaccine and that it was only 
successful in animals challenged with SIVsmE660 but not with SIVmac251
246.  These 
limitations underscore the difficulty of protecting against a heterologous challenge.   
  There have been other promising approaches to HIV-1 vaccine design.  One study 
used a rhesus CMV viral vector to deliver Gag, Rev/Nef/Tat, Env, and Pol in order to 
establish a persistent T-cell response
247.  Although these vectors were unable to protect 
the animals from challenge, about half of the vaccine-treated animals were able to clear 
the viral infection, and virus was not detected in any reservoir tissues as measured by the 
most sensitive PCR techniques.  However, despite the inclusion of Env in the viral 
vector, there were little to no Env-directed antibodies produced.  If such a vaccine were 
able to produce Env antibodies, it might more efficiently prevent initial infection. 
4.B. Developing antigens that will generate HIV-1 bNAbs 
It will take major advances in antigen design in order to generate a bNAb 
response.  HIV-1 bNAbs have a large amount of necessary somatic hypermutation in 99 
 
their framework region and usually have long CDR-H3s.  This degree of somatic 
hypermutation may hinder the therapeutic usefulness of these antibodies.  Reverting these 
antibodies back to their germline sequences might limit this immunogenic response.  
However, many such germline mutations impact the neutralization potency of these 
antibodies
248.  New antigens designed to elicit bNAbs from their germline precursor will 
need to take these factors into account. 
To develop a useful antigen, we need a better understanding of the coevolution of 
the virus and antibody maturation process by which bNAbs emerge.  Recently, one group 
tracked the mutations of a founder virus as it changed the glycosylation on N332, a 
supersite of vulnerability to current glycosylation bNAbs
249.  Over the course of the 
infection, a glycosylation site emerged after six months but it later reverted.  Both non-
glycosylated variants were resistant to PGT128.  This type of study provides insight to 
the interplay between the evolving virus and generation of bNAbs that may prove useful 
in vaccine design.   
An effective subunit vaccine may require rational structure-based antigen design.  
For example, McLellan et al designed variants of RSV F in the pre-fusion state that 
maintained the antigenic site Ø
250.  Immunization of these stable RSV F variants in mice 
and macaques elicited a neutralizing antibody response that was able to protect the 
animals from RSV infection.  Although RSV is considerably easier to neutralize than 
HIV-1, it is conceivable that this idea can be extended to HIV-1 Env or gp120.  Variants 
of Env that expose vulnerable sites, like the CD4-binding site, may accelerate the 
maturation of neutralizing antibodies that specifically target that site.  In any case, an 100 
 
antigen(s) eliciting neutralizing antibodies will be a critical component of a successful 
HIV-1 vaccine. 
4.C. Soluble trimeric Env as an antigen   
The recently published crystal structure of the Env trimer may be useful for 
vaccine design
82,251.  A soluble Env trimer antigen can elicit antibodies that recognize 
quaternary epitopes.  Unfortunately, a soluble trimer still has the same fatal flaw that a 
gp120 antigen has: it is only one Env.  An evolving Env may be necessary to drive  high 
levels of somatic hypermutations found on bNAbs.  Thus, a stepwise approach using 
antigens that continually target and mature a specific germline precursor might be 
necessary.  A recent study that evaluated the antibody development pathway after HIV-1 
infection showed that V1/V2 loop antibodies could be generated within months of 
infection
240.  Interestingly, these antibodies had modest somatic hypermutation and long 
CDR-H3s.  These results suggest that HIV-1 bNAbs, under the optimal conditions, might 
only take weeks to develop rather than years.   
4.D.  Antibody cocktails as a new HIV-1 therapy   
Until a conventional vaccine is available, we must consider alternate approaches.  
Our data imply that targeting multiple epitopes on Env can generate greater potency than 
targeting one epitope from one inhibitor or bNAb.  Specifically, we show that the CD4- 
and coreceptor-binding sites can be targeted simultaneously for potent neutralization, 
either by two antibodies or a fusion construct.  Although both the receptor epitopes are 
highly conserved, they are a challenge to target.  CD4bs antibodies are rare and difficult 
to elicit with a single antigen.  In general, CD4i antibodies are not potent and only 101 
 
neutralize tier 1 HIV-1 isolates.  CD4i antibodies also have difficulty accessing the 
coreceptor-binding site because of the V1/V2 and V3 loops surrounding the epitope. 
  The field has already recognized the value of using bNAbs in a cocktail therapy 
for treating HIV-1 infection
188-190.  A cocktail of 3 to 5 bNAbs was effective at 
suppressing infection in a humanized mouse model while combinations of 2 to 3 bNAbs 
could suppress SHIV infection in rhesus macaques.  Interestingly in these latter studies, 
PGT121 by itself could suppress SHIV-SF162P3 infection in 3 out of 4 macaques
190.  
Considering the potency of PGT121 and breadth of 10E8, using antibody cocktails as a 
therapy that combines a variety of epitopes like the CD4-binding site, V1/V2 loop 
glycosylation, V3 loop glycosylation, and MPER, may be effective at suppressing a wide 
range of HIV-1 infection. 
There are a few obstacles that currently face the antibody cocktail therapy.  First 
is the possibility of escape mutants from the antibodies used in the cocktail.  If the 
antibodies target multiple epitopes, there is a greater chance of success at suppressing a 
wide range of HIV-1 isolates.  However, an isolate may already be resistant to all but one 
of the antibodies in the cocktail.  Should this be the case, escaping the last remaining 
antibody is less difficult than escaping multiple antibodies.  This scenario raises the 
possibility of using variants of an antibody to cover escape mutation pathways.  NIH45-
46
G54W has been engineered with this idea in mind.  NIH45-46m2 and NIH45-46m7 
variants were just as potent as the predecessor antibody and combining all three 
antibodies did not allow for any escape mutants to occur in a humanized mouse model
145.  
Even with this success, it is still unclear whether a cocktail should target a single epitope, 
anticipating multiple escape pathways, or multiple distinct epitopes. 102 
 
Because no known antigen can elicit a response that is similar to a bNAb cocktail,  
passive transfer or gene therapy delivery of the antibody cocktail remain the only viable 
approaches.  Passive transfer studies have shown most of these bNAbs to have a half-life 
of 2 days post injection in humanized mice
188.  In rhesus macaques injected with an 
inoculum of 20 mg/kg of antibody, titers decreased to low concentration levels by day 7 
post injection.  In order to make passive transfer a viable therapy, new technologies need 
to be developed in order to increase the time the antibody lasts in the host.  Gene therapy 
viral vectors bypass the need for continuous passive administration.  Numerous studies, 
including our own, have shown that AAV vectors can be effectively used for the constant 
production of immunoadhesins or antibodies by muscle cells
129,232,252,253.  Questions still 
remain of the long term production of such inhibitors but data suggest that their 
production can continue for two years or more.  However, the consequence for long-term, 
high-level antibody production in the absence of infection must be better understood.  
Going forward, studies would need to address potential problems such as host responses 
against the antibodies and how to stop antibody expression should problems arise. 
4.E. Translating bNAb in vitro properties   
There are general concerns about the non-neutralizing functions of bNAbs and 
whether in vitro potency translates into an in vivo model.  The TZM-bl neutralization 
assay determines the potency of an antibody against a large panel of HIV-1 isolates.  
Although this assay can determine potency and breadth of an antibody, it only accounts 
for neutralizing cell-free virus, which might not determine activity in an in vivo model.  It 
is not clear that this assay predicts the efficacy of antibodies and Env inhibitors against T-
cell associated viral reservoirs.  Newly developed in vitro assays determine whether these 103 
 
antibodies can neutralize cell-to-cell transmission of virus.  Flow cytometry analysis has 
been utilized to show that these antibodies can limit cell-to-cell spread
254.  It is clear that 
if antibodies will be used therapeutically, more physiological systems may be necessary 
to assess in vivo potency of a bNAb.  The field is now closely evaluating the non-
neutralizing effector functions of antibodies and how they influence protection.  This was 
apparent in the RV144 Thai trial where there were apparent ADCC antibodies.  These 
antibodies may be one subset of antibodies for a vaccine to elicit should they have a role 
in protection. 
4.F. The role of CD4i antibodies in an HIV-1 vaccine   
Both studies presented here highlight the importance of blocking coreceptor 
binding.  First, we showed that E51, an antibody whose epitope overlaps the coreceptor 
binding site, can increase the potency of the CD4bs antibodies by increasing the 
association for Env through quaternary changes.  Second, fusing a CCR5mim peptide to 
CD4-Ig increased the binding of CD4-Ig to Env, limited enhancement of infection by 
CD4-Ig, and increased avidity presumably by binding multiple epitopes on a single Env.  
Currently, the available CD4i antibodies are at the state most bNAbs were at 5 years ago: 
poorly neutralizing and lacking breadth.  Is it worth undertaking a search for better CD4i 
antibodies?  Identifying additional CD4i antibodies may not be difficult.  An antigen 
could be engineered such that a gp120 monomer would be held in the CD4-bound state 
by fusing CD4 to gp120.  This would create an accessible CD4i epitope for B cells to 
target.  Identifying antibodies of this class from a library is straightforward.  Key 
features, such as VH1-69 lineage or a tyrosine-sulfation motif in the CDR-H3, would be 
helpful in quickly identifying those antibodies that target the CD4i epitope. 104 
 
Although we can generate and identify new CD4i antibodies, it remains unclear 
whether new CD4i antibodies will be more potent than current antibodies in this class.  
As we and others have shown, CD4i antibody binding requires quaternary changes in Env 
and incur an entropy cost as they induce the open conformation on Env.  The potent HIV-
1 bNAbs – VRC01, PGT121, etc. – have low Env perturbation factors that allow for 
higher affinity binding and faster on-rates
140.  Any CD4i antibody may necessarily incur a 
free energy cost as it binds because its epitope is occluded or differently structured in the 
absence of CD4.  The energy required to induce the open state of Env could limit the 
potency and breadth of any CD4i antibody.  Further, the coreceptor epitope is smaller 
than that of the CD4-binding site.  Antibodies directed to the CD4i epitope will have 
numerous contact residues that are highly variable, again limiting their breadth and 
enabling viral escape. 
  CD4i antibodies may therefore have limited application.  However, our data 
suggests a role for CD4i antibodies in a possible HIV vaccine.  The potent CD4bs 
antibodies can be thought as having two key properties: they block access to CD4 and 
they avoid promoting necessary coreceptor binding.  However, less potent CD4bs 
bNAbs, like F105, have been shown to have higher perturbation factors compared to 
more potent ones and may induce the CD4i epitope
140.  The presence of CD4i antibodies 
might enhance the neutralization of these high perturbation factor CD4bs antibodies 
4.G. Using eCD4-Ig as a vaccine alternative   
The absence of a silver bullet antigen to elicit HIV-1 bNAbs raises the question 
whether we can develop better therapies for treating HIV-1 infection.  Use of a single 
entry inhibitor almost inevitably leads to viral escape.  However, we have shown that 105 
 
eCD4-Ig, through its mechanistically distinct mode of neutralization that targets the CD4- 
and coreceptor-binding sites simultaneously, is a highly potent entry inhibitor and has 
breadth that is unmatched by any HIV-1 antibody.  Its exceptional breadth likely derives 
from the fact that, unlike antibodies, eCD4-Ig specifically targets only the most 
conserved regions on gp120.  As escape from eCD4-Ig is characterized, it will be 
interesting to see what kind of fitness cost the virus pays in order to gain resistance to the 
inhibitor.  Nonetheless, it appears that eCD4-Ig has the unique properties useful as a 
vaccine alternative or therapy. 
  Passive administration of any new therapy, including bNAbs, is not currently 
feasible, but, as we demonstrate, ssAAV vectors can produce large amounts of functional 
eCD4-Ig in rhesus macaques.  To determine the efficacy as eCD4-Ig as a vaccine 
alternative or therapy, we are developing higher-powered rhesus macaque studies to 
determine if these levels of eCD4-Ig (>100 µg/mL in serum) can protect from both SHIV 
and SIV infection.  Given that AAV vectors take 4-6 weeks to produce these levels of 
eCD4-Ig, it will be necessary to suppress viral load with antiretroviral drugs so the virus 
does not escape as the transgene expression ramps up.  Although it has been suggested 
that one antiviral drug might limit AAV transduction, an easy alternative to drugs is a 
bridge of a high-dose passive transfer of eCD4-Ig during AAV inoculation.  In either 
case, given enough time for transgene expression, anti-retroviral drug and/or passive 
administration therapy could be ended while AAV therapy continues production of 
eCD4-Ig to maintain viral suppression. 
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4.H. Predicting escape pathways of eCD4-Ig 
  As mentioned, we are developing an in vitro model of eCD4-Ig escape.  We have 
currently shown that eCD4-Ig neutralizes 100% of the HIV-1, HIV-2, and SIV isolates 
assayed.  However, isolates resistant to eCD4-Ig may still exist.  By consistently 
passaging virus in the presence of eCD4-Ig in vitro and in macaques, we expect to gain 
insight on pathways by which the virus can mutate in order to become resistant to eCD4-
Ig.  There are several possibilities.  First, the virus could adapt and become less 
dependent on CD4 binding, thus relying more on coreceptor usage.  CD4-independent 
viruses tend to be X4 viruses and eCD4-Ig can efficiently neutralize this subset of 
viruses.  However, subtle mutations around the CD4-binding site may occur.  These 
mutations could alter the structure of binding region such that the virus decreases its 
affinity for CD4, decreasing affinity for the CD4 portion of eCD4-Ig.  Similarly, subtle 
mutations might emerge in sulfotyrosine-binding pocking of the coreceptor-binding site.  
Should escape occur because of changes to either receptor-binding site, we anticipate a 
corresponding cost to viral fitness. 
  A more likely escape pathway may include changes in the variable loop regions.  
If we assume the “claw-like” binding by eCD4-Ig on Env, the repositioning of the V1/V2 
loop could sterically exclude eCD4-Ig.  As modeled in Figure 4.1 (based on the 
mechanism we assume eCD4-Ig binds Env from our biochemical and neutralization 
studies), the V1/V2 loop in the cryo-EM of Env is in close proximity to the Fc portion of 
eCD4-Ig.  CD4 binding relocates the V1/V2 loop to create the open form of Env and a 
longer V1/V2 loop has a greater chance of interfering with the eCD4-Ig Fc domain, 
preventing its peptide portion from binding.  SIV neutralization studies with the rh-107 
 
eCD4-Ig
mim2 suggest this possibility.  The original rh-eCD4-Ig
mim2 construct included 
rhesus IgG2 as the Fc.  When we changed the Fc to rhesus IgG1, we observed a marked 
increase in the potency of rh-eCD4-Ig
mim2.  Specifically, the hinge of rhesus IgG1 is six 
amino acids longer than rhesus IgG2.  We hypothesize that the longer hinge allows for 
greater flexibility for eCD4-Ig to reach around the V1/V2 domain and bind Env with its 
sulfopeptides.  Consistent with this, SIVmac239 Env has a V1/V2 loop of 100 amino 
acids, much longer than the average 70 amino acids of HIV-1.  The longer IgG1 hinge 
likely limits steric interference from the V1/V2 loop of SIVmac239. 
 
Figure 4.1.  Modeling Env escape from eCD4-Ig.  Here we show the cryo-EM structure of Env with two 
gp120 subunits modeled into their respective locations.  In red is CD4 and the the sulfotyrosines atoms are 
modeled in green.  The Fc receptor has been modeled in approximately to the location for where CD4 
would reach around to have the sulfopeptides bind gp120.  Distances are included for determining how far 
the Fc would need to reach in order to get the sulfopeptides to bind in a “claw-like” state.  Labeled is the 
location of the V1/V2 loop in the CD4-bound state.  The V1/V2 loop is repositioned following CD4 
binding.  eCD4-Ig puts Env in the CD4-bound state, thus the V1/V2 loop would be repositioned outward.  
A longer V1/V2 would sterically interfere with the Fc domain of eCD4-Ig as it tries to reach around to bind 
the sulfopeptides at the C-terminus to their respective epitopes on Env.  Thus, using the IgG1 Fc is 
beneficial for eCD4-Ig binding. 108 
 
    Lastly, escape mutations might emerge in the V3 loop.  The sulfotyrosine-binding 
pocket is at the base of the V3 loop which is repositioned after CD4 binding to enable 
access for the coreceptor.  Mutations or insertions in the V3 loop could prevent access for 
the sulfopeptide to bind in two ways.  Mutations might lead to changes in the structure of 
the V3 loop that make it less flexible, thus making it harder to access the sulfotyrosine-
binding pockets.  Alternatively, larger V3 loops might also make the sulfotyrosine-
binding pockets more inaccessible by occluding this site.  In either case, the virus may 
exploit subtle differences in between the CCR5 N-terminus and the CCR5mim1 region of 
eCD4-Ig to allow the former but not the latter to bind. 
4.I. Effectively using AAV vectors for HIV-1 therapy  
eCD4-Ig is an antibody-like inhibitor with the potential to outperform even the 
broadest and most potent HIV-1 bNAbs.  However, in contrast to bNAbs, there will never 
be an antigen developed to elicit eCD4-Ig in vivo.  Thus, AAV vectors are necessary for 
use of eCD4-Ig in an in vivo model.  Although earlier studies showed that scAAV vectors 
can produce large amounts of transgene
129, we were only able to observe about 5 to 12 
µg/mL of eCD4-Ig when using scAAV vectors.  However, ssAAV vectors allowed us to 
incorporate a larger CMV promoter and the WPRE to stabilize RNA expression, which 
increased eCD4-Ig expression to levels >100 µg/mL.  These levels should be sufficient to 
prevent SHIV and SIV infection in rhesus macaques and may be useful as a therapeutic. 
  Use of AAV vectors for gene therapy is not novel to the HIV field.  Although it is 
not the traditional sense of a vaccine, such an approach is closer to realization than a 
conventional vaccine.  Protection has been observed in mouse and macaque studies using 
AAV vectors, yet human studies present several hurdles.  A major concern is the lack of 109 
 
an off-switch – a mechanism that stops the expression of the transgene – in the event of a 
poor reaction to the AAV expressed transgene.  The idea of an off-switch has already 
been realized in other gene therapy approaches through the uses of inducible caspase 
9
255,256.  For similar strategy to be applied to AAV delivery of HIV-1 antibodies, the off-
switch will have to be smaller in size.  Another question is whether it is healthy for a 
patient to maintain high levels of a single, unchanging antibody.  Without an off-switch, 
the only viable method for eliminating transgene expression would be a muscle biopsy, 
which has not been evaluated.   
  Another concern resides with the bNAbs themselves.  These antibodies are fully 
matured, most with a large CDR-H3 and extensive somatic hypermutation.  At high 
concentrations, these antibodies will likely elicit an endogenous antibody or a cytoxic T 
cell response.  As stated above, attempting to mutate some of these residues back to 
germline sequences limits the potency of these antibody so a certain number of mutations 
will have to be retained.  Barouch et al. observed a faster viral rebound after a second 
dose of PGT121 which may be a result of a secondary anti-PGT121 response
190.  More 
data on the safety of these antibodies will be required before they are considered as a 
viable therapy. 
  Finally, AAV-delivery presents additional problems.  Maximum eCD4-Ig 
expression was observed at 6 to 10 weeks post AAV-innoculation, providing a window 
for viral escape.  The lower concentrations of an inhibitor found in the early stages might 
allow and drive escape before AAV transgene production reaches therapeutic 
concentrations.  Horowitz et al. examined the use of anti-retroviral drugs with AAV 
expressed bNAbs 3BNC117 and 10-1074.  It was reported that only half the mice that 110 
 
received the AAV injection had efficient expression of antibody
257.  To circumvent 
potential problems combining the anti-retrovirals with AAV, a bridge of passively 
administered antibody was delivered while AAV inoculation was being performed.  The 
majority of the mice receiving this treatment were able to maintain suppression of viral 
loads even after the bridge of passive antibody administration was stopped.  Overall, 
some form of initial treatment to suppress the viral load must be undertaken for an AAV-
based therapy to be effective. 
  Use of AAV to deliver antibodies is not limited to HIV-1 therapy.  Broadly 
neutralizing anti-influenza antibodies are as difficult to elicit as HIV-1 antibodies.  
Current data suggests antibodies targeting the stalk of HA are the broadest and most 
potent because the stalk is a highly conserved, yet highly protected, area of HA.  These 
antibodies are rare and come from the VH1-69 germline.  Without a proper antigen to 
target this germline precursor, AAV-based therapy can be again applied to prevent and 
treat influenza A virus.  Balasz et al. showed that their AAV vector efficiently produced 
an anti-HA influenza antibody, F10, in mice and that these treated mice were protected 
from subsequent influenza challenges
253.  As experience with delivery of AAV vectors 
for antibodies deepens, this class of therapeutics could be applied towards other 
pathogens lacking vaccines like dengue virus and malaria parasites, at least until 
conventional vaccines are developed. 
4.J. Other gene therapy ideas to be considered 
  Using AAV vectors to deliver HIV-1 inhibitors that target Env is one possibility.  
Alternatively, one target the HIV-1 receptors themselves.  As mentioned in the 
introduction, an antibody fused with the PG9 or PG16 scFv domains efficiently blocks 111 
 
HIV-1 entry through the localization of the scFv domains to Env.  Like eCD4-Ig, 
PG9/PG16-iMab could be expressed using AAV vectors.  Another target for antibodies 
would be CCR5.  One study showed that an anti-CCR5 vaccine protected a subset of 
macaques for SIV infection
258.  PRO140 is an anti-CCR5 antibody that blocks HIV-1 
entry in vitro that was already evaluated in Phase 2 clinical trials.  Like bNAbs, we could 
use AAV vectors to express PRO140 in vivo and be used as an alternate to an HIV-1 
vaccine.  However, in both cases, the safety of such approaches will be an even greater 
concern. 
Interestingly, one gene therapy study targeted the CCR5 gene, excising it from T 
cells.  Some populations, mainly in Scandinavia, have inherited a partially deleted CCR5 
gene in chromosome 3 termed CCR5-Δ32.  This CCR5 deletion renders these people 
resistant to R5 strains of HIV-1 without apparent consequences.  Using this insight, 
Tebas et al. modified CD4+ T cells of HIV-1(+) patients using zinc-finger endonucleases 
to delete the CCR5 gene
259.  The modified T cells were then infused into their donors and 
no side effects were noted in any of the 12 patients in this phase I clinical trial.  Data also 
showed that viral copies decreased and the modified T cells continued to proliferate.  
Moving forward, there are many gene therapy approaches that can be applied to limit 
replication in HIV-1 infected individuals. 
4.K. Closing remarks 
  Our data indicate that it is useful and effective for an HIV-1 entry inhibitor to 
target multiple epitopes of Env.  Specifically, targeting the CD4- and coreceptor-binding 
sites of Env by a combination of CD4bs and CD4i antibodies is more efficient than 
targeting either site alone.  Viral escape is less likely when multiple epitopes are targeted 112 
 
so a vaccine that can generate neutralizing antibodies against several sites on Env, 
including the coreceptor binding site, should be considered.  However, we are still many 
steps away from having a conventional vaccine that can elicit bNAbs.  Numerous studies 
have shown that when using gp120 monomers or trimers to elicit Env antibodies, at best 
these antibodies neutralize a subset of tier 2 isolates.  Although there is a role for non-
neutralizing antibody effector functions, like ADCC, bNAbs are likely necessary for a 
vaccine to effectively protect from infection.  However, bNAbs are probably not 
sufficient.  An effective vaccine should make use of both arms of the immune system as 
these responses are tightly integrated and in combination is what protects us from disease. 
  Until an effective HIV-1 vaccine is developed, the field continues to pursue 
alternative prophylactic and therapeutic approaches.  Cocktails of current bNAbs can be 
effective, but without an efficient mechanism of delivery, this therapy will likely not be 
practical.  Even with more efficient means of passive administration, in which an 
antibody cocktail is administered every four months or so, this approach cannot be 
readily applied in developing nations.  Although there are a number of concerns with 
using AAV vectors, they could transform bNAbs into a realistic therapy.  Our data 
suggest that eCD4-Ig can be just as effective as the current bNAbs and should be 
considered as a possible vaccine alternative alone or in combination with bNAbs should 
AAV vectors prove to be safe and efficient as therapies.  Our future studies will focus on 
the efficacy of eCD4-Ig in animal models as we attempt to develop eCD4-Ig into a new 
HIV-1 therapy. 
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